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Abstract: This work reviews the neuropharmacology of the vestibular system, with an emphasis on the mechanism of  
action of drugs used in the treatment of vestibular disorders. Otolaryngologists are confronted with a rapidly changing 
field in which advances in the knowledge of ionic channel function and synaptic transmission mechanisms have led to the 
development of new scientific models for the understanding of vestibular dysfunction and its management. In particular, 
there have been recent advances in our knowledge of the fundamental mechanisms of vestibular system function and  
drug mechanisms of action. In this work, drugs acting on vestibular system have been grouped into two main categories 
according to their primary mechanisms of action: those with effects on neurotransmitters and neuromodulator receptors 
and those that act on voltage-gated ion channels. Particular attention is given in this review to drugs that may provide  
additional insight into the pathophysiology of vestibular diseases. A critical review of the pharmacology and highlights of 
the major advances are discussed in each case. 
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INTRODUCTION 
  Vertigo, dizziness and imbalance are the main symptoms 
of vestibular disorders. These symptoms can lead to physical 
consequences such as reduced postural control and falls and 
to psychological and psychiatric consequences such as de-
pression, anxiety, panic, agoraphobia, and cognitive defects, 
especially in the elderly [98]. The goal of the treatment of 
vestibular disorders should be to control symptoms, reduce 
functional disability and improve the quality of life of the 
patients. This article reviews the neuropharmacology of ves-
tibular disorders with an emphasis on the mechanism of ac-
tion of drugs used in the treatment of such disorders and with 
emphasis on drugs that, due to their mechanisms of action, 
may provide additional insight into the physiopathology of 
vestibular disease. Drugs that by their systemic effect could 
secondarily affect vestibular function are not included in the 
review. 
   Therapeutic options for the treatment of vestibular dis-
eases  are  restricted  to  pharmacological  treatments,  reposi-
tioning maneuvers, surgical particle liberation, and rehabili-
tation [96, 164]. At peripheral end organs, drugs that act on 
the vestibular apparatus have diverse cellular targets. These 
targets are involved in the homeostasis of liquids and electro-
lytes in the inner  ear,  in the regulation of blood flow and 
cellular homeostasis and survival, and in the modification of 
sensory processes including mechanoelectrical  transduction 
in  hair  cells  and  postransductional  processing  of  sensory 
information. In vestibular nuclei, in the central nervous sys-
tem, drug effects are more difficult to define due to the com-
plexity of the neural systems involved in vestibular informa-
tion processing. We have centered our analysis of drugs with  
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central effects on those acting on neurotransmitter receptors 
and ion channels.  
  From a pharmacological point of view, it is important to 
emphasize that the central portion of the vestibular system is 
isolated  from  the  systemic  blood  flow  by  the  blood-brain 
barrier, whereas the periphery of the vestibule is isolated by 
the  blood-labyrinthic  barrier.  Because  of  this,  some  drugs 
can affect one region without affecting the other. Strategies 
have also been designed that allow the local administration 
of some drugs, thus limiting their systemic effects. 
DRUGS  WITH  EFFECTS  ON  NEUROTRANSMIT-
TERS AND NEUROMODULATOR RECEPTORS 
  In the inner ear, hair cells of the vestibular neuroepithe-
lium  establish  synapses  with  afferent  neurons  and  receive 
innervation  from  the  efferent  neuronal  system.  The  main 
neurotransmitter of hair cell afferent synapses is glutamate; 
efferent neuronal synapses release acetylcholine as the pri-
mary  neurotransmitter  (Fig.  1).  Glutamate  released  at  hair 
cell afferent synapses interacts with several subtypes of exci-
tatory  amino  acid  (EAA)  receptor,  including  N-methyl-D-
aspartic  acid  (NMDA),  α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionic acid (AMPA), kainic acid (KA) recep-
tors,  and  metabotropic  receptors  [7,  38,  52,  73,  116,  137, 
139].  The  NMDA  receptors  participate  in  determining  the 
basal  discharge  and  tonic  response  to  sustained  stimuli, 
whereas non-NMDA receptors seem to mediate responses to 
high-frequency mechanical stimulation [39, 139]. 
  Hair cells and efferent neurons also release diverse neu-
roactive substances, including calcitonin gene related peptide 
(CGRP), substance P, opioid peptides, endocannabinoids, γ-
aminobutyric acid (GABA), ATP, adenosine and histamine 
[38, 52]. Apart from the neurotransmitters that participate in 
the  processing  of  sensory  information,  the  vestibule  also 
receives sympathetic and parasympathetic innervation, a fact Neuropharmacology of Vestibular System Disorders  Current Neuropharmacology, 2010, Vol. 8, No. 1    27 
that probably accounts for the presence of catecholamines in 
the inner ear [47].  
  Vestibular  system  primary  afferent  neurons  make  syn-
apses with neurons of the vestibular nuclei, where they re-
lease glutamate and, probably, aspartate as neurotransmitters. 
The neurons of the vestibular nuclei send glutamatergic, cho-
linergic and GABAergic projections to numerous parts of the 
central  nervous  system  (CNS),  including  the  cerebellum, 
oculomotor nuclei, contralateral vestibular nuclei, autonomic 
nuclei,  spinal  cord,  thalamus  and  cerebral  cortex  [13,  60, 
161].  The  vestibular  nuclei  receive  projections  originating 
from the visual system, particularly from the accessory opti-
cal system (a system that play a role to differentiate a sub-
ject’s  own  movements  from  environmental  ones)  and  the 
visual cortex. Vestibular nuclei also receive proprioceptive 
signals, especially from cervical regions, from the cerebel-
lum and from diverse fibers that originate from diencephalic 
nuclei. The numerous and diverse synaptic inputs to the ves-
tibular nuclei form part of the very complex integrative proc-
esses  involved  in  postural  control  and  gaze  stabilization 
[131]. 
  The neurons of the vestibular nuclei also express NMDA 
and non-NMDA EAA receptors [26, 49, 158]. Among other 
functions, these receptors mediate the main excitatory input 
to the vestibular nuclei neurons that originates from the pri-
mary afferents [31, 115, 148]. EAA receptors alter their ex-
pression in a dynamic manner; for example, NMDA recep-
tors mediate a long-lasting depression that forms a signifi-
cant part of  the  mechanism  that suppresses  the  activity of 
neurons from the vestibular nuclei following labyrinth abla-
tion [60, 130]. In addition to the EAA receptors mediating 
the input from the vestibular periphery, neurons of the vesti-
bular nuclei express a variety of neurotransmitter receptors 
that mediate the many integrative influences that these nuclei 
receive (Fig. 2). Among these are GABA-A and GABA-B 
receptors and glycine receptors that show an extensive colo-
calization with GABA receptors, histamine H1, H2 and H3 
receptors  [15],  serotonine  5HT1  and  5HT2  receptors  [56], 
adrenergic α2 receptors, but also α1 and β receptors [124], 
cholinergic muscarinic (mACh) and nicotinic (nACh) recep-
tors in all the vestibular nuclei [92], opioid receptors [146, 
147], canabinoid CB1 receptors [132], neurotrophin Trk A, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The scheme depicts the synaptic relationships of type I (right) and type II (left) hair cells. The type I hair cells are characterized by 
the large chaliceal afferent innervation that covers its basolateral surface. The efferent fibers make synaptic contacts with the external surface 
of the calyx in the afferent neuron. In type II hair cells, the afferent neurons form button type synapses, and the efferent neurons make synap-
tic contact directly upon the hair cell body. The hair cell to afferent synapse uses glutamate as the principal neurotransmitter. At the postsyn-
aptic cell glutamate interacts with several subtypes of excitatory amino acid (EAA)-receptors including N-methyl-D-aspartic acid (NMDA), 
α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid (AMPA), kainic acid (KA) and metabotropic receptors. The efferent neurons are 
primarily cholinergic, and ACh released from afferent neurons interacts with muscarinic (mACh) and nicotinic (nACh) receptors. The effer-
ent neurons also release calcitonin gene related peptide (CGRP), substance-P and enkephalins, which act on specific receptors (in the case of 
the enkephalins κ−opioid receptor in the hair cells and µ−opioid receptors in the afferent neurons). Both the hair cells and the afferent neu-
rons expressed the nitric oxide synthase (NOS) and produced nitric oxide (NO). Hair cells also express H1 histamine receptors and the affer-
ent neurons H3 histamine receptors. The hair cells typically express purinergic receptors (ATP) in their apical portion. 28    Current Neuropharmacology, 2010, Vol. 8, No. 1  Soto and Vega 
B and C receptors (for a review, see [27]) and finally, gluco-
corticoid receptors.  
  All these synaptic inputs to the vestibular nuclei partici-
pate in the development of various physiological processes 
and its study have contributed to the knowledge of the inte-
grative physiology of the vestibular nuclei and to the many 
pathophysiological mechanisms involved in vestibular disor-
ders. Commissural GABAergic inhibition seems to be exclu-
sively mediated by GABA-A receptors, the activity of which 
is  antagonized  by  bicuculline  and  enhanced  by  benzodi-
azepines [41, 165]. Serotonergic and dopaminergic innerva-
tion of the vestibular nuclei may account for the association 
that  has  been  observed  between  vestibular  alterations,  
anxiety disorders and migraine [10, 40].  The activation of 
glucocorticoid receptors seems to play an important role in 
processes  leading  to  vestibular  compensation;  this  would 
explain the beneficial action of neuroactive steroids, such as 
dexamethasone, in vestibular plasticity [22].  
  The main output of the vestibular nucleus neurons is cho-
linergic,  but  these  neurons  also  produce  other  neuroactive 
substances such as nitric oxide, which seems to play a sig-
nificant  role  in  vestibular  compensation  processes  [133]. 
Processes related with nitric oxide may account for some of 
the collateral effects of drugs widely used in the clinic, such 
as sildenafil, that can typically produce alterations in vision, 
including  diplopia  and  dizziness  in  2%  of  patients.  These 
events have been exclusively attributed to the cardiovascular 
effects  of  the  drugs,  but  it  seems  equally  likely  that  they 
could be caused by alterations in vestibular activity, which, 
to  our  knowledge,  has  not  been  studied  in  such  patients.  
In  fact,  there  are  reports  of  patients  who  develop  severe  
vestibular symptoms after a single 50 mg dose of sildenafil 
[57]. 
  The complexity of the synaptic connections determining 
the activity of the afferent neurons in the vestibular end or-
gans, together with the intricate synaptology of the vestibular 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The scheme depicts the complexity of synaptic input impinging on the vestibular nucleus neurons. It is necessary to consider that the 
neurons of the nuclei are heterogeneous and not all cells necessarily receive all types of synaptic influences. The main synaptic input to the 
vestibular nuclei neurons is from the primary afferents, mediated by glutamate that interacts with NMDA, AMPA/KA and metabotropic re-
ceptors. Vestibular nuclei also receive glutamatergic synapses originating from spinal cord neurons. GABAergic fibers originating primarily 
from the cerebellum and from the contralateral vestibular nuclei impinge on the vestibular nucleus neurons, activating GABA-A and GABA-
B receptors. Histaminergic fibers originating from the tuberomammillar nucleus act on H1, H2 and H3 receptors. Serotonergic fibers originat-
ing from the raphe nuclei activate 5-HT1 and 5-HT2 receptors. Intrinsic and commissural connections give rise to glycinergic fibers acting 
on glycine inhibitory receptors. Noradrenergic fibers originating from the locus coeruleus act primarily on α2 receptors, but also on α1 and β 
receptors. Internuclear enkephalinergic fibers that release orphanin-nociceptin F/Q acting on ORL1 receptors (opioid-like orphan receptor) 
and δ-opioid receptors also make a synaptic input to certain neurons in the nuclei. The endocannabinergic type CB1 receptors have also been 
detected in the vestibular nuclei. The output of the vestibular nuclei neurons is primarily by glutamatergic and cholinergic projections, but 
GABAergic and glycinergic projections have been demonstrated also. Finally, the vestibular nucleus neurons express the NOS and may pro-
duce NO as a cellular messenger. Neuropharmacology of Vestibular System Disorders  Current Neuropharmacology, 2010, Vol. 8, No. 1    29 
nucleus, determines that many drugs acting on synaptic re-
ceptors may influence the activity of the vestibular system. 
For a synopsis of the drugs acting on neurotransmitter recep-
tors treated in this work see Table 1. 
Drugs Acting on Excitatory Amino Acid Receptors (EAA 
Receptors) 
  Diverse pathophysiogenic models have demonstrated the 
role  of  EAA  receptors  in  excitotoxicity  [30].  Changes  in  
intracellular  ion  concentrations,  particularly  alterations  in  
the homeostasis of intracellular calcium secondary to EAA 
receptor  over-activation,  seem  to  induce  oxidative  stress  
and the generation of free radicals [128]. For this reason, it 
has been proposed that EAA receptor antagonists, as well as 
calcium channel antagonists, exert a neuroprotective action 
in  cases  of  ischemia  or  over-activation  of  EAA  mediated 
synapses. In the cochlea such over-activation may occur as a 
result of intense sound exposure; in the case of the vestibule, 
it could be caused by continuous movement. It also seems 
possible that an excitotoxic process may develop in postural 
vertigo in which semicircular canal stimulation is sustained. 
  Trimetazidine  (1-(2,3,4  trimethoxybenzyl)  piperazine 
hydrochloride) is an anti-ischemic agent that has been used 
in cardiac ischemic disturbances and tested in the sympto-
matic treatment of vertigo. Although its mechanism of action 
is not still completely defined, trimetazidine inhibits excito-
Table 1.  Drugs with Effect on Neurotransmitter Receptors 
Trimetazidine   Noncompetitive EAA-R antagonist  Ischemia or conditions cursing with  
over-activation of the afferent input 
Memantine  Noncompetitive NMDA-R antagonist. With  
serotonergic 5HT3-R, dopaminergic D2-R, and  
cholinergic mACh-R and nACh-R antagonism 
Used to control acquired pendular nystagmus 
Dizocilpine   NMDA-R antagonist   Neuroprotective agent in cases in which  
aminoglycoside use was required 
Neramexane  Noncompetitive NMDA-R and 
α9α10-containing nACh-R antagonist 
Phase III clinical trials for tinnitus control. ¿Can it be useful  
for ischemia or as neuroprotective for vestibular disorders? 
Scopolamine and  
atropine 
Competitive mACh-R antagonists  The most commonly used drug in vestibular disorders.  
Most effective drugs for the treatment of motion sickness 
Diphenidol   Anticholinergic effect due to interactions with mACh-R  Prevention and symptomatic treatment of peripheral  
(labyrinthine) vertigo and associated nausea and vomiting.  
Control of nausea and vomiting of any origin 
Betahistine  H3-R antagonistic and a partial, weak  
agonistic of H1 and H2 receptors 
Most used drug in the Ménière's disease control in  
Europe. Reduces the incidence and severity of vertigo  
and the incidence of nausea and emesis 
Diphenhydramine  Antagonist of H1 and of ACh receptors  Most used drug in the Ménière's disease control in USA 
Meclizine and cyclizine  Antagonist of H1 and of ACh receptors  Commonly used in combination with betahistine or  
diphenhydramine in the Ménière's disease control 
Promethazine  Antagonist of H1 and of ACh receptors  Treatment and prevention of vertigo 
Diazepam, lorazepam  
and clonazepam 
GABA-A receptor antagonists  Therapeutic effect in vertiginous syndromes, apart from  
their sedative and anxiolytic action that significantly  
contributes to the well-being of patients 
Baclofen  GABA-B receptor antagonist  Used to control periodic alternating nystagmus 
Gabapentin  GABA-A receptor agonist 
Slight Ca
2+ channel block 
Used to control pendular nystagmus 
Phentanyl   Synthetic primary MOR agonist  Used in the treatment of Ménière's disease crises  
and vestibular neuronitis in combination with droperidol 
Droperidol  Dopaminergic receptor antagonist   Usually an antipsychotic. Useful for treatment  
of acute peripheral vertigo 
Sulpiride  Selective D2 receptor antagonist  Used as a vestibular sedative 
Excitatory amino acid receptor, EAA-R; N-methyl-D-aspartic acid receptor, NMDA-R; Type 3 serotonergic receptor, 5HT3-R; Type 2 dopamine receptor, D2-R; Nicotinc acetylcho-
line receptor, nACh-R; Muscarinic acetylcholine receptor, mACh-R; Type 1, 2 or 3 histamine receptor, H1-, H2- or H3; Type A or B γ-aminobutyric acid, GABA; µ-opioid receptor, 
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toxic  damage  induced  by  the  activation  of  EAA  receptors 
[46], possibly by acting as a modulator of aerobic glycolysis, 
with  a  consequent  decrease  in  lactic  acid  production. 
Trimetazidine  selectively  suppresses  mitochondrial  3-
ketoacyl  coenzyme  A  thiolase,  thereby  reducing  free  fatty 
acid  metabolism  and  balancing  cardiac  metabolism;  these 
actions contribute to its anti-oxidative stress activity and to 
its  ability  to  diminish  mitochondrial  damage  in  cases  of 
ischemia [29]. Using voltage clamp recording in rat vestibu-
lar ganglion neurons, trimetazidine has been shown to block 
intracellular calcium increase and ionic current produced by 
the  application  of  EAA  receptor  agonists  KA  and  AMPA 
[28].  Antagonism  of  AMPA/KA  receptors  of  afferent  
neurons can explain the beneficial effects of trimetazidine. It 
is possible that, in additional to its peripheral neuroprotective 
effect,  trimetazidine  could  also  modulate  glutamatergic  
neurotransmission  and  cellular  metabolism  in  vestibular  
nuclei, although no reports of this effect were found. 
  In clinical tests, trimetazidine is as effective as betahis-
tine  in  the  treatment  of  vertigo  and  dizziness  [91];  multi-
center studies have confirmed the utility of trimetazidine in 
diverse  disorders  that  produce  balance  alterations  [3]  and, 
although  discreet,  in  the  reduction  of  the  frequency  and  
duration of vertigo in Ménière's disease patients [111]. It is 
worth  noting  that  trimetazidine  can  induce  parkinsonism, 
gait disorders and tremor, and at least one case of coreiform 
manifestations  related  to  its  use  has  been  described  [89, 
129]; for this reason, its use is not advisable in patients with 
any  predisposition  to  Parkinson’s  or  any  type  of  tremor-
related diseases. 
  Memantine (1-amino-3,5 dimethyiladamantane) is a low-
affinity  noncompetitive  NMDA  receptor  antagonist,  al-
though some reports indicate that it also acts on serotonergic 
5HT3 receptors, dopaminergic D2 receptors and cholinergic 
muscarinic  and  nicotinic  receptors.  Memantine  has  been 
used in the treatment of Parkinson’s disease and some de-
mentias,  including  Alzheimer’s  disease.  In  the  inner  ear, 
memantine  blocks  the  response  of  the  vestibular  afferent 
neurons to NMDA receptor agonists [103], although currents 
through  α9/α10  nicotinic  receptors  in  cochlear  outer  hair 
cells were also blocked by memantine,
 with an IC50 of about 
1 µM [104]. It has been suggested that transtympanic appli-
cation  of  memantine  might  have  a  clinical  use  because  it 
limits potential systemic effects [128]. Various case reports 
have proven the beneficial effect of memantine on acquired 
pendular nystagmus. Nevertheless, no controlled studies that 
demonstrate its utility in the treatment of vestibular disorders 
have been published [145]. Somewhat similar results have 
been reported for caroverine, a derivative of quinoxaline that 
acts like a competitive antagonist of the AMPA receptor; no 
controlled studies that support its use in the clinical treatment 
of vestibular disorders have been published. 
  Three noncompetitive antagonists of the NMDA recep-
tor, including dizocilpine (dibenzo-cycle-penteno-imine, also 
referred to as MK-801), ketamine and phencyclidine, have a 
significant use in basic research and have also been the sub-
ject of clinical studies. Ketamine was used as a dissociative 
anesthetic. Dizocilpine was used as a neuroprotective agent 
in cases in which aminoglycoside use was required, under 
the hypothesis that cellular damage caused by aminoglyco-
sides is due to overactivation of NMDA receptors and a sub-
sequent excitotoxic process [14, 37, 58]. However, clinical 
trials  showed  insignificant  protective  action  of  dizocilpine 
against aminoglycoside ototoxicity. From our point of view, 
this was an expected result because there are no data indicat-
ing  that  hair  cells,  which  constitute  the  primary  cell  type 
affected by the aminoglycosides, express NMDA receptors. 
In fact, streptomycin exerts an antagonistic action on EAA 
receptors [109] and also blocks mechanoelectrical transduc-
tion  in  vestibular  hair  cells  [78].  Phencyclidine  is  a  well 
known noncompetitive NMDA receptor antagonist because 
it is frequently used as a recreational drug (PCP or “angel 
dust”);  it has  important effects on vestibular activity. Spe-
cifically, acute poisoning with phencyclidine induced intense 
horizontal and vertical nystagmus due to its inhibitory action 
on synaptic input to neurons of the vestibular nuclei [100]. 
At the moment, phencyclidine has no known clinical use in 
vestibular pharmacology. 
  A more recent addition to the set of EAA receptor-acting 
drugs is neramexane, a novel amino-alkyl-cyclohexane de-
rivative that is a noncompetitive NMDA receptor antagonist. 
This compound displaced [(3)H]-MK-801 binding to rat cor-
tical membranes with K(i) values between 1 and 100 µM and 
antagonized inward current responses of cultured hippocam-
pal neurons to NMDA in a strongly voltage-dependent man-
ner with rapid blocking/unblocking kinetics [45]. Studies on 
recombinant  rat  α9α10  nicotinic  acetylcholine  receptors 
expressed in Xenopus laevis oocytes show that neramexane, 
as  well  as  memantine,  blocks  acetylcholine-evoked  re-
sponses in a noncompetitive manner [113]. The authors con-
sider that “clinically relevant concentrations of neramexane 
blocked  native  α9α10-containing  nicotinic  acetylcholine 
receptors of rat inner hair cells, thus demonstrating a possi-
ble  in  vivo relevance in potentially unexplored  therapeutic 
areas” [113]. 
Drugs Acting on Acetylcholine Receptors 
  Vestibular type II hair cells and vestibular afferent neu-
rons are innervated by efferent neurons (Fig. 1), which exert 
central  control  of  the  vestibular  responses  based  on  the 
movement  programs  of  the  subject.  The  efferent  neurons 
originate  bilaterally  in  the  brain  stem,  in  a  region  located 
dorsolateral to the genus of the facial nerve in the proximity 
of the abducens nucleus and ventral to the medial vestibular 
nucleus  [20,  108].  The  efferent  neurons  that  innervate  the 
vestibular neuroepithelia are positive for choline acetyltrans-
ferase, acetylcholinesterase (AChE), CGRP, and enkephalins 
[108, 121].  
  The stimulation of efferent fibers produces complex ef-
fects on the activity of vestibular afferent neurons, increas-
ing, inhibiting or having mixed biphasic effects on the elec-
trical  discharge  of  the  afferent  neurons  [16,  50,  59,  154]. 
Studies  using  cloning  techniques  and  the  reverse  tran-
scriptase-polymerase chain reaction (RT-PCR) have shown 
that  ACh  nicotinic  receptors  in  the  vestibular  neuro- 
epithelia  are  formed  essentially  of  α9/α10  subunits  [36],  
although  in  adult  rats,  transcripts  encoding  the  α2-7  and  
β2-4 nAChR subunits were found in the vestibular ganglia 
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nAChR  subunits  were  expressed  in  the  vestibular  neuro- 
epithelia  [5].  In  situ  hybridization  histochemistry  data  
suggest  that  nAChRs  composed  of  α4  and  β2  subunits  
are  localized  on  afferent  chalices  innervating  type  I  
vestibular hair cells and that the direct cholinergic efferent 
innervation of  type II vestibular hair  cells utilizes nAChR 
composed of other subunits [159]. In addition to nicotinic 
receptors,  muscarinic  receptors  (m1,  m2  and  m5)  were  
expressed  in  human  vestibular  afferent  neurons,  whereas  
in the rat, five subtypes of muscarinic receptors (m1 - m5) 
are found [160]. Muscarinic receptors have been the target  
of  many  of  the  drugs  used  in  the  treatment  of  vestibular  
disorders.  
  Cholinergic  input  has  been  identified  in  all  vestibular 
nuclei [92]. The application of acetylcholine to the vestibular 
nuclei of cats produced an activation similar to that induced 
by stimulation of the primary afferent neurons; the activation 
was  enhanced  by  AChE  inhibitors  and  reduced  by  mACh 
antagonists such as scopolamine. The neurons of the vestibu-
lar nuclei release ACh as a neurotransmitter; for this reason, 
they also express choline acetyltransferase [13, 149].  
  Among the drugs that modulate cholinergic activity, sco-
polamine and atropine have the most significant clinical ap-
plication for the treatment of vestibular disorders. Other cho-
linergic  drugs  like  physostigmine  (also  known  as  eserine) 
and neostigmine have been used experimentally to induce a 
motion sickness-like syndrome. 
  Scopolamine  (also  known  as  butylscopolamine  and 
hyoscine butylbromide) and atropine are alkaloids of natural 
origin; both are nonselective competitive inhibitors of mACh 
receptors. Physostigmine (eserine) and neostigmine are cho-
linomimetics that inhibit acetylcholinesterase in the CNS and 
the peripheral nervous system, respectively. Both inhibitors 
bind to the active site of the enzyme and reduce hydrolysis of 
acetylcholine for up to four hours. 
  Scopolamine is most commonly used drug in vestibular 
disorders. It is one of the most effective drugs for the treat-
ment of motion sickness; nevertheless, it has not yet been 
determined whether its effect takes place at the peripheral or 
central vestibular system [67, 160]. A recent study analyzed 
the literature (14 works, 1025 subjects) comparing the effec-
tiveness of scopolamine and other agents  employed in  the 
prevention  and  treatment  of  motion  sickness.  The  results 
indicate  that  scopolamine  produced  a  significantly  greater 
favorable effect than placebo and that there is no significant 
difference  in  the  effectiveness  of  scopolamine  and  that  of 
calcium  channel  antagonists,  antihistaminics,  methylsco-
polamine  or  a  combination  of  scopolamine  and  ephedrine 
[141]. Frequent collateral effects of the use of scopolamine 
are  blurred  vision  and  dry  mouth;  occasionally,  confusion 
also appears. Low doses of scopolamine or atropine produce 
a  transitory  tachycardia  associated  with  the  peak  of  their 
effect (90 minutes after oral scopolamine). Due to the short 
average life of scopolamine in plasma and its adverse effects, 
the clinical use of orally administered scopolamine is lim-
ited. To diminish the incidence of adverse effects, a system 
of transdermal dosage by means of patches has been devel-
oped. These patches are available by prescription and contain 
1.5 mg scopolamine, of which 5 µg/h is released, maintain-
ing scopolamine plasma levels approximately constant over 
8-9 days [101, 119].  
  Contrary to the action of mACh antagonists, the admini-
stration  of  physostigmine,  an  AChE  inhibitor,  produced  a 
motion sickness-like syndrome, including nausea, vomiting, 
discomfort, anxiety, and increases in ACTH, beta-endorphin, 
cortical and prolactin plasma levels [69]. In fact, physostig-
mine administration can be used as a model for the study of 
motion sickness and of the space adaptation syndrome and to 
detect individuals’ susceptibility to the development of these 
syndromes.  Whereas  scopolamine  facilitates  adaptation  to 
movement  in  experimental  animals,  physostigmine  sup-
presses this adaptation; interestingly, neostigmine (an AChE 
inhibitor that typically acts on the peripheral nervous system 
because it cannot cross the blood-brain barrier) does not have 
any significant vestibular effects. This indicates that central 
cholinergic systems play an essential role in the process of 
adaptation to movement [99]. 
  Diphenidol  (1,1-diphenyl-1-piperidinebutanol)  has  been 
used  for  many  years  in  the  prevention  and  symptomatic 
treatment of peripheral (labyrinthine) vertigo and associated 
nausea and vomiting that occur in such conditions as  Mé-
nière's disease and surgery of the middle and inner ear, as 
well  as  for  the  control  of  nausea  and  vomiting  associated 
with postoperative states, malignant neoplasm, labyrinthine 
disturbances,  antineoplastic  agent  therapy,  radiation  sick-
ness, and infectious diseases. In patients with Ménière's dis-
ease,  double-blind  studies  showed  that  use  of  diphenidol 
results in better control of symptoms than the administration 
of placebo [42]. Although the mechanism of action of diphe-
nidol on the vestibular system has not yet been elucidated, it 
exerts  an  anticholinergic  effect  due  to  interactions  with 
mACh  receptors,  particularly  m1,  m2,  m3  and  m4  [155]. 
Hence,  its  actions may take place  at  the vestibular nuclei, 
where a significant excitatory input is mediated by ACh re-
ceptors,  and  also  at  the  vestibular  periphery  where  mACh 
receptors are expressed at efferent synapses [110]. Recently, 
a series of selective mACh-receptor antagonists based on the 
diphenidol molecule has been synthesized, but they have not 
yet been the subject of clinical trials [155]. 
Drugs Acting on Histamine Receptors 
  Four histaminergic receptors, designated H1 to H4, have 
been identified. All belong to the superfamily of G-protein 
coupled, seven transmembrane segment receptors. Typically, 
in the CNS, H1 and H2 receptors are found at postsynaptic 
terminals, while H3 receptors show a presynaptic localization 
in nonhistaminergic cells, where they function like heterore-
ceptors.  H4  receptors  are  typically  found  outside  the  CNS 
[61, 84].  
  The histaminergic fibers in the CNS originate from the 
tuberomammillary  nucleus  of  the  posterior  hypothalamus. 
These neurons have a spontaneous, slow, and regular action 
potential  discharge.  The  activity  of  the  tuberomammillar 
neurons varies in the day-night cycle: it is high during wake-
fulness, reduced during slow-wave sleep,  and stops during 
rapid eye movement sleep [21]. The histaminergic neurons 
constitute a highly divergent system that project diffusely to 
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paths [106]. Immunohistochemical studies reveal a moder-
ately dense histaminergic innervation projecting to the four 
vestibular nuclei [60, 151, 168]. These fibers consist of me-
dium diameter nonmyelinated axons that exert neuromodula-
tory actions in the vestibular nuclei [80]. 
  The  possibility  that  histamine  could  act  like  a  neuro-
transmitter or a neuromodulator at peripheral vestibular end 
organs was suggested by the finding that astemizole, an H1-
receptor  antagonist  that  does  not  penetrate  the  hematoen-
cephalic  barrier,  suppresses  nystagmus  in  patients  with 
chronic dizziness [68]. Later, it was demonstrated that his-
tamine  and  other  imidazole-containing  substances  increase 
the ampullar nerve afferent firing rate, while both H1 and H2 
histamine  antagonists  inhibited  ampullar  nerve  activity.  A 
specific inhibitor of histidine decarboxylase, the enzyme that 
catalyzes the synthesis of histamine, reduced ampullar nerve 
firing in a dose-dependent manner [65]. The use of agonists 
and antagonists of H1, H2 and H3 receptors allowed investi-
gators to determine that H1 and probably also H3 receptors 
are functionally expressed in vestibular end organs [53]. In 
the hair cells of the crista ampullaris of the guinea pig, intra-
cellular calcium changes produced by the application of 10 
µM histamine were blocked by H1, H2 and H3 antagonists 
(promethazine, cimetidine and thioperamide) [152].  
  Studies using RT-PCR and immunoblotting and immu-
nocytochemical experiments in frog and mouse semicircular 
canal  sensory  epithelia  showed  that  both  frog  and  mouse 
vestibular epithelia express H1 receptors, although no clear 
evidence for H3 receptor expression in hair cells was found 
[19]. However, RT-PCR analysis showed the presence of H3 
receptor mRNA in mouse vestibular ganglia, and H3 protein 
expression was found in vestibular neurons characterized by 
large  and round soma, which showed positive staining for 
calretinin and calbindin [153].  
  One of the remaining problems with respect to the role of 
histamine in the vestibular system end organs is the origin of 
histamine.  Histamine  receptors  are  expressed  in  the  inner 
ear,  but  we  do  not  know  the  source  of  the  endogenous 
ligands  for  these  receptors.  The  possibility  has  been  sug-
gested that the endogenous mediator is not histamine but a 
related substance such as carnosine or N-acetylhistidine and 
that the effects of histamine antagonists occur through com-
petition  with  these  endogenous  analogs  of  histamine  [33, 
65]. This could account for the tonic activation of histamine 
receptors and for the effect of histamine antagonists on the 
basal discharge of vestibular afferent neurons [25]. 
  In the central nervous system, histamine modulates  the 
activity of the second order vestibular neurons, and different 
effects have been observed depending on the experimental 
paradigm used. In vivo studies using iontophoresis of hista-
mine showed a decrease in the discharge frequency of vesti-
bular nucleus neurons in cats [76]; in contrast, in vitro stud-
ies using slices of the vestibular nucleus found that histamine 
produced an increase in the discharge frequency of medial 
vestibular nucleus (MVN) neurons in rats and guinea pigs 
[80]. Studies using whole-cell patch recording demonstrated 
that histamine excited lateral vestibular nucleus (LVN) neu-
rons by activation of postsynaptic H2 receptors [168]. The 
MVN is mainly involved in both eye and head control, par-
ticularly in the horizontal plane, whereas LVN seems mainly 
to integrate the information of linear acceleration and grav-
ity’s changes of the body to control vestibulo-spinal reflexes 
and posture [168]. 
  Among the antihistaminics, betahistine, diphenhydramine 
(usually  in  combination  with  theophylline),  meclizine,  its 
derivate  cyclizine,  and  promethazine  have  been  the  most 
commonly  used  in  the  medical  treatment  of  vertigo.  In 
Europe, betahistine is more frequently used. A prospective 
study  in  England  demonstrates  that,  for  the  treatment  of  
Ménière's  disease,  92%  of  doctors  prescribe  betahistine 
[134]. In contrast, in the United States, the antihistaminics 
most commonly used in the treatment of vestibular disorders 
are diphenhydramine, meclizine (1[(4-chlorophenyl)-phenyl-
methyl]-4-[(3-methylbenzyl)methyl] piperazine), its derivate 
cyclizine  and  promethazine.  The  phenothiazines  (pro-
methazine  and  prochlorperazine)  are  the  most  frequently 
prescribed  antiemetic  drugs  [96].  All  these  antihistaminics 
are  primarily  H1  receptor  antagonists,  but  they  also  have  
an  anticholinergic  effect  that  is  more  remarkable  in  the  
case of promethazine [166]. Their actions are both central 
and peripheral, although the central action seems essential 
because  antihistaminics  that  do  not  cross  the  blood-brain 
barrier did not show usefulness in the treatment of vertigo. 
All of them cause an important sedation and, due to its po-
tential anticholinergic effect, meclizine must be administered 
with caution in patients with asthma, glaucoma or prostate 
hypertrophy.  
  Although betahistine is not approved for use in the man-
agement of vestibular syndromes in the United States, it is 
the  drug  most  commonly  used  in  the  European  countries, 
Canada  and  Latin  America  for  the  treatment  of  Ménière's 
disease [134]. Controlled studies demonstrate that betahistine 
was  the  most  effective  when  compared  with  cinnarizine, 
clonazepam, flunarizine or Ginkgo biloba administered for 
120 days to patients diagnosed with Ménière's disease. For 
patients with peripheral vestibular alterations different from 
Ménière's disease, betahistine was as effective as cinnarizine 
or clonazepam, and all three were more effective than flu-
narizine or EGb 761 (standardized extract of Ginkgo biloba) 
[43]. Studies using a combination of cinnarizine and dimen-
hydrinate indicate that this combination could be more effec-
tive than betahistine in the treatment of patients with vertigi-
nous syndromes of peripheral origin, making it a good and 
safe alternative to standard therapy with betahistine for the 
treatment of Ménière's disease acute episodes and in long-
term therapy [54, 102]. 
  Betahistine is an analog of histamine that has an antago-
nistic action on H3 receptors [9]. It also has a partial, weak 
agonist effect on H1 and H2 receptors [61, 162]. In rat brain 
stem slices, betahistine produced a slight excitatory action on 
neurons of the MVN and, in spite of its apparent weak po-
tency, significantly reduced the excitatory effect of histamine 
[64]. When administered in a sustained form to cats, betahis-
tine  significantly  alters  histamine  turnover  in  neurons  of  
the tuberomammillary nucleus [150]. In the vestibular end 
organs  of  rodents  and  amphibians,  betahistine,  as  well  as  
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discharge frequency of the vestibular afferent neurons [17, 
18, 25].  
  Since the introduction of betahistine, it has been reported 
that its administration significantly reduces the incidence and 
severity of vertigo and produces a decrease in the incidence 
of nausea and emesis [1, 51, 75, 79, 81, 97, 98]. Its clinical 
effect has been attributed to increased blood flow in the ves-
tibular system and cochlea [90]. Electrophysiological studies 
have established that the clinical action of betahistine is most 
probably produced by an inhibitory influence exerted at the 
vestibular nuclei and at the peripheral end organs; this inhibi-
tory action modulates the afferent sensory input and the re-
lease of other neurotransmitters and reestablishes the bilat-
eral balance of activity in the afferent neurons [25, 53, 138]. 
  It is worth noting that antihistaminics cause a depression 
of  the  central  nervous  system,  which  imposes  a  serious  
limitation when the activities of the subject require alertness; 
for this reason, in certain cases, it is possible to use antihis-
tamines  in  combination  with  amphetamines  [107].  Pro-
methazine is especially known to cause drowsiness, which is 
often counteracted by ephedrine in a combination known as 
“the Coast Guard cocktail.” 
Drugs with Effects on GABA Receptors  
  The possible role of GABA in the vestibular periphery 
has been widely discussed without reaching a clear definition 
of its function in synaptic transmission in vestibular end or-
gans [62, 94, 157]. GABAergic pathways from the cerebel-
lum  and  commissural  fibers  from  the  contralateral  nuclei 
exert  a  powerful  inhibitory  input  on  the  vestibular  nuclei, 
activating  both  GABA-A  (ionotropic)  and  GABA-B  (me-
tabotropic) receptors [60, 131].  
  Diazepam is the most widely used benzodiazepine in the 
treatment  of  vestibular  disorders,  although  lorazepam  and 
clonazepam are also frequently used. Clonazepam is particu-
larly useful in the treatment of migraine-related vertigo and 
postural  vertigo.  Diazepam,  a  typical  GABA-A  receptor 
agonist, significantly reduces the spontaneous electrical ac-
tivity  of  neurons  in  the  medial  vestibular  nuclei,  exerting 
both pre- and post-synaptic actions on diverse groups of neu-
rons [62, 63, 125]. The inhibitory effect of the benzodiazepi-
nes on the electrical activity of the vestibular nuclei leads to 
its  therapeutic  effect  in  vertiginous  syndromes,  apart  from 
their sedative and anxiolytic action that significantly contrib-
utes to the well-being of patients [55, 166]. 
  Baclofen, a selective agonist of  the GABA-B receptor, 
has shown a promising effect, particularly in the treatment of 
uncompensated vestibular asymmetry in animal models [55]. 
Baclofen presumably acts by enhancing inhibition in vestibu-
lar nuclei and related networks, consequently reducing nys-
tagmus in patients with vestibular alterations. A few studies 
showed that baclofen improves periodic alternating nystag-
mus [167]. In contrast, the GABA-A receptor agonist gabap-
entin  (probably  also  acting  on  calcium  channels)  acts  on 
pendular nystagmus [145]. 
Drugs with Action on the Opioid Peptide Receptors 
  Like  other  neurotransmitters  and  their  receptors, 
enkephalins and opioid receptors are expressed in both the 
central and the peripheral nervous systems. Opioid peptides 
have been detected in auditory and vestibular efferent neu-
rons, where they colocalize with the major neurotransmitter, 
acetylcholine. RT-PCR, in situ hybridization, Western blots 
and  immunohistochemistry  have  shown  the  expression  of 
Mu-opioid receptor (MOR)  in Scarpa's ganglia  and cristae 
ampullaris  of  the  rat.  MOR  transcript  was  detected  in  the 
soma of the vestibular afferent neurons. These results indi-
cate that MOR may mediate some of the synaptic influences 
of  vestibular  efferent  neurons  on  afferent  neurons  [114]. 
Functionally,  the  opioid  receptors  exert  a  complex  neuro-
modulatory action on vestibular end organs. They exert an 
inhibitory presynaptic action on hair cells and an excitatory 
postsynaptic  action  in  afferent  neurons.  In  hair  cells,  the  
activation  of  kappa-opioid  receptors  inhibits  the  calcium 
current,  decreasing  afferent  activity.  The  activation  of  
Mu-opioid  receptors  on  afferent  neurons  potentiates  the  
action  of  excitatory  amino  acids,  increasing  the  afferent  
activity [156]. This type of opposed pre- and postsynaptic 
action  is  typical  of  opioid  receptors  and  accounts  for  
the  state-dependent  activity  of  opiate  neurotransmitters.  It  
is  worth  noting  that  the  α9/α10  nAChR,  with  its  peculiar 
sensitivity  to various agents,  is a target for modulation by 
endomorphin-1 and dynorphin-B, efferent cotransmitters in 
the inner ear [87]. 
  The opioids also make an important contribution to the 
operation of vestibular nucleus neurons [131]. Enkephalin-
containing cell bodies and nerve terminals are found in the 
medial vestibular nucleus, and a few substance P-containing 
neurons have been found in vestibular nuclei [93]. Microion-
tophoretic application of enkephalin produced an inhibition 
of the electrical discharge of neurons of the medial vestibular 
nucleus, as well as a decrease in its response to glutamate, 
suggesting  that  opioids  modulate  the  afferent  input  to  the 
nuclei [74]. The agonist of the opioid receptor like-1 (ORL-
1)  nociceptin,  as  well  as  [D-Ala2,  D-Leu5]-enkephalin 
(DADLE: an agonist of the delta opioid receptor), also exert 
an inhibitory effect on the electrical activity of MVN neu-
rons. The application of nociceptin in the rat diminishes the 
gain of the vestibulo-ocular reflex [146, 147].  
  The finding that opioids affect the excitability of the in-
ner ear explains why diverse drugs of abuse, such as heroin 
and  more  recently  dihydrocodone,  can  produce  significant 
alterations in hearing and balance. In fact, there are reports 
of the occurrence of a Ménière's like-syndrome after the use 
of epidural morphine [86]. The combination of phentanyl (a 
synthetic primary MOR agonist 100 times more potent than 
morphine) and droperidol (an antidopaminergic drug used as 
an antiemetic and antipsychotic) has been used for the treat-
ment  of  Ménière's  disease  crises;  this  mixture  has  a  rapid 
action  and  results  in  a  complete  suppression  of  vestibular 
activity in normal subjects and in those with Ménière's dis-
ease [32]. Administration of a single dose of phentanyl and 
droperidol combination (droperidol 5 mg, phentanyl 0.1 mg) 
to patients undergoing acute episodes of vestibular disease 
(vestibular neuronitis and Ménière's disease) was effective in 
the following symptoms and/or signs: nausea, vertigo, nys-
tagmus, the positive past-pointing test and the Romberg test 
[71].  Droperidol  alone  is  also  remarkably  effective  in  de-
pressing vestibular disturbance, regardless of etiology. How-34    Current Neuropharmacology, 2010, Vol. 8, No. 1  Soto and Vega 
ever, no difference has been found between the therapeutic 
efficacies  of  intramuscular  injection  of  droperidol  and  
dimenhydrinate for the treatment of acute peripheral vertigo 
[66].  
Drugs Acting on Amine Receptors 
  Drugs  that  affect  biogenic  amine  receptors  have  been 
widely used in the  therapy of diverse vestibular disorders; 
there  is  consensus  that their  effects  are  exerted  essentially  
at the central nervous system, not specifically in vestibular 
nuclei,  although  these  have  an  important  noradrenergic,  
serotonergic and dopaminergic input [60].  
  Amphetamines  improve  tolerance  to  stimulation  with 
rotations  [163].  The  use  of  amphetamines  in  combination 
with  scopolamine  or  antihistaminics  increased  the  antiver-
tiginous effect and reduced the secondary sedation produced 
by  antihistaminics  and  anticholinergic  drugs.  Ephedrine 
seems to be as effective as amphetamines in increasing the 
effectiveness  of  drugs  used  for  the  control  of  movement  
disease, but without the addictive potential of amphetamines.  
  The application of dopamine (0.1-1 mM) and D1 and D2 
agonists induced a dose-dependent and reversible decline in 
the resting discharge frequency of vestibular afferents in the 
isolated frog vestibule [6]. The responses of afferent neurons 
to EAA agonists were inhibited by D1 and D2 agonists, im-
plicating both subtypes of dopamine receptors in the modula-
tion  of  both  ionotropic  and  metabotropic  glutamate  recep-
tors. The results obtained suggest that dopamine may interact 
with both D1 and D2 receptor subtypes that are most likely 
located postsynaptically on the afferent neurons, where they 
may form part of the efferent control of vestibular input [6]. 
These findings coincide with those of previous studies that 
indicate  the  participation  of  catecholamines  in  vestibular 
neurotransmission [47] and contribute to understanding the 
mechanism of action of dopaminergic-related drugs, such as 
droperidol, in the treatment of vestibular disorders. In fact, 
sulpiride, which is a selective antagonist at postsynaptic D2 
receptors, has been used as a “vestibular sedative”.  
Drugs Acting on Cannabinoid Receptors  
  It has recently been established that cannabinoids play an 
important  role  in  the  activity  of  neurons  of  the  vestibular 
nuclei through the activation of cannabinoid CB1 type recep-
tors [132]. There is also evidence suggesting the expression 
of cannabinoid receptors in vestibular end organs [23]. These 
results indicate the possibility of using cannabinoid-related 
drugs in the treatment of vestibular alterations, particularly 
now that several drugs with effects on these receptors  are 
available [120]. Although much information is available on 
the  use  of  cannabinoids  to  control  chemotherapy-induced 
alterations, including dizziness and emesis, as far as we have 
been able to determine, no double-blind and well controlled 
studies  addressing  cannabinoid  use  in  vestibular  disorders 
are available.  
DRUGS  ACTING  ON  VOLTAGE-GATED  IONIC 
CHANNELS 
  Almost all cells of an organism express a set of mem-
brane  ion  channels.  Nevertheless,  ion  channels  acquire  
special relevance  in the physiology of excitable cells.  The 
definition of an important set of channelopathies that affect 
inner  ear  function  and  the  identification  of  the  functional 
roles  of  diverse  subtypes  of  ion  channels  in  the  inner  ear  
has allowed substantial expansion of the use of drugs with 
effects  on  these  membrane  proteins.  Knowledge  of  ion  
channel  function  offers  therapeutic  possibilities  for  the  
rational design of new drugs and drug combinations. Impor-
tantly, it has been proposed that pathologies as complex as 
Ménière's disease might have their origin in channelopathies, 
particularly in those cases in which there is a clear familial 
expression of the disease [44]. For a synopsis of the drugs 
acting on voltage-gated ionic channels treated in this work 
see Table 2. 
Table 2.  Drugs with Effect on Voltage-Gated Ionic Channels 
Dihydropyridines: nimodipine,  
nitrendipine 
L type Ca
2+ channel blocker  Management of vertigo of  
peripheral origin 
Cinnarizine and flunarizine  L type Ca
2+ channel blocker 
Slight H1 antihistaminic action. 
Potential antagonism of nACh-R  
Cinnarizine also acts as a pressure-sensitive  
potassium channel blocker 
Management of vertigo of peripheral origin 
Verapamil  L type Ca
2+ channel blocker  Management of vertigo of peripheral origin 
Lidocaine  Na
+ channel blocker  Transtympanic infusion of lidocaine with  
dexamethasone for the 
management of acute vertigo and in the long-term  
management of patients with Ménière's disease 
Carbamazepine   Stabilizes the inactivated state of the  
voltage-dependent Na
+ channel 
Treatment of vestibular paroxysms 
3,4-diaminopyridine  Blocker of Kv1 (KCNA) family of  
voltage-activated K
+ channels 
Control of the nystagmus in patients with type 2  
(EA2) episodic ataxia 
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Calcium Channel Blockers 
  The  ubiquity  of  calcium  channels  determines  that  cal-
cium channel blockers can exert diverse effects at the central 
and at the peripheral vestibular system. From the pharmacol-
ogical point of view, the participation of calcium channels in 
neurotransmitter release at synaptic terminals constitutes the 
primary therapeutic target of calcium channel blockers, al-
though the calcium-activated potassium current may also be 
a significant target contributing to the action of these drugs 
[34].  Neurotransmitter  release  in  hair  cells  is  mediated  by 
high voltage-activated calcium channels (CaV1.3) that can be 
blocked by dihydropyridines [4, 8, 11, 112]. 
  The expression of type L, N, P and Q calcium channels 
has  been  demonstrated  in  primary  afferent  neurons  of  the 
vestibular system [24]. All these channels, identified on the 
basis of their biophysical and pharmacological characteris-
tics,  participate  in  generation  of  the  action  potential  dis-
charge and in control of the excitability of afferent neurons 
by the activation of the calcium-activated potassium current 
[85]. The calcium currents that occur in the afferent neurons 
also participate in neurotransmitter release at the vestibular 
nuclei.  
  Neurons of the vestibular nuclei express high threshold L 
and N-type calcium channels as well as low threshold T-type 
calcium  channels  [126,  127].  Hence,  the  calcium  channel 
blockers  affect  the  input  and  output  of  information  of  the 
vestibular  nuclei.  Depending  on  the  functional  role  of  the 
subtypes  of  channel  in  each  synapse,  the  effect  of  some 
blockers could be greater than others, leading to selectivity 
[135]. At synapses in the central nervous system, the calcium 
channels participating  in neurotransmitter release are N or 
P/Q-type.  These channels are not blocked by  the dihydro-
pyridines. In contrast, in the hair cell to afferent neuron syn-
apse,  they  are  dihydropyridine  sensitive L -type  channels. 
Since the majority of the agents used in clinics are derived 
from dihydropyridines the effect of these drugs is primarily 
peripheral. 
  The most commonly used calcium channel blockers for 
the  management  of  vestibular  disorders  are  nimodipine, 
nitrendipine (a dihydropyridine with long lasting effect) and 
verapamil. Other long lasting dihydropyridines such as am-
lodipine, felodipine, nicardipine and nifedipine  are seldom 
used [55, 83, 123].  
  The piperazine derivates cinnarizine and flunarizine, both 
of  which  have  an  antihistaminic  action,  have  been  widely 
used  in  the  treatment  of  vestibular  disorders.  Cinnarizine, 
besides its L-type calcium channel blocking action [8], acts 
as  a  blocker  of  the  pressure-sensitive  potassium  channels. 
This may be relevant in the vestibule, since this last type of 
channel can be activated when inner ear endolymphatic hy-
drops  develops  [34,  35].  In  addition,  cinnarizine  and  flu-
narizine have antihistaminic action (acting on H1 receptor) 
and  potential  (although  very  weak)  nicotinic  receptor  an-
tagonism.  Disappointingly,  no  studies  have  evaluated  the 
exact role of these actions in the therapeutic effect of these 
drugs [117]. 
  The  dihydropyridines  nimodipine  and  nitrendipine  are 
typical L-type calcium channel blockers [95] and exert their 
effect on the calcium currents in hair cells, inhibiting afferent 
neurotransmitter  release  [4,  112].  Verapamil,  although  it 
belongs  to  a  different  chemical  class  of  fenilalkilamines 
typically  used  for  its  antiarrhythmic  action,  has  also  been 
successfully used in the management of vestibular migraine 
syndrome [118]. 
  There are reports that suggest a significant effectiveness 
of cinnarizine on the management of vertigo of peripheral 
origin. A multinational and multi-center double blind study 
compared the effectiveness of cinnarizine (150 mg per day) 
with that of nimodipine (30 mg three times per day). After 
12 weeks of treatment, nimodipine decreased the incidence 
of moderate attacks of vertigo by 79%, and those of severe 
vertigo  by  85%;  whereas  cinnarizine  reduced  attacks  of 
moderate  vertigo  by  66%  and  of  severe  vertigo  by  90% 
[105].  
  Gabapentin (Neurontin), which was originally thought to 
act exclusively on GABA receptors, also has a blocking ef-
fect  on  calcium  channels,  specifically  binding  to  the  α2δ 
subunit of these channels [82]. This drug has been used in 
the treatment of vertigo and certain types of nystagmus of 
central origin [142]. 
  Independently of their effects at the vestibular level, the 
blockade of calcium channels has a negative inotropic effect 
and  antimigraine  action.  Calcium  channels  also  modify  
diverse cellular signals related to apoptosis. In fact, because 
patients with vestibular alterations have a high prevalence of 
migraine, the blocking of calcium channels (particularly by 
verapamil  and  nimodipine)  offers  an  additional  advantage 
because of its anti migraine effect [118]. 
Drugs Acting on Sodium Channels 
  Diverse types of sodium channels are expressed  in  the 
inner  ear  neuroepithelia.  Among  them,  the  TTX-sensitive 
NaV1.7 plays a fundamental role in the action potential dis-
charge in afferent neurons and in the neurons of vestibular 
nuclei. Sodium currents participate in the ontogeny of hair 
cells  and mediate the generation of the action potential in 
neurons. Pharmacological modification of sodium channels 
produces significant changes in the excitability and discharge 
pattern of the afferent neurons [26, 136]. 
  In a rat  experimental model, transtympanic  infusion of 
lidocaine produces a vigorous spontaneous nystagmus that 
reaches  its  maximum  after  20  min  of  drug  administration 
[88].  This  is  consistent  with  the  known  sodium  channel 
blocking action of lidocaine. Its use produces a functional, 
reversible ablation of the inner ear. There are clinical reports 
indicating that transtympanic infusion of lidocaine with dex-
amethasone could have a significant beneficial effect in the 
management of acute vertigo and in the long-term manage-
ment  of  patients  with  Ménière's  disease.  With  the  use  of 
transtympanic lidocaine in a group of 113 patients, 83% ex-
perienced an immediate lightening of the sensation of full-
ness of the ear and dizziness; a year after treatment 69% of 
these  patients  still  showed  remission  of  symptoms  [122]. 
Nevertheless, in these studies lidocaine was combined with 
corticoids;  therefore,  it  is  difficult  to  judge  which  drug 
caused the effect.  More recently, the use of transtympanic 
lidocaine in treatment of Ménière's disease has been reevalu-36    Current Neuropharmacology, 2010, Vol. 8, No. 1  Soto and Vega 
ated. Transtympanic instillation of a solution of 4% lidocaine 
with furfuryladenine produced a remarkable improvement in 
the vestibular symptoms in 87.5% of patients; 67% of these 
patients were free of attacks after approximately 26 months 
of follow up. In this work, as in the previously cited studies, 
lidocaine was coapplied with other drugs, in this case N(6)-
furfuryladenine,  which  is  a  natural  stable  secondary  DNA 
damage product with very well defined cytokine and anti-
aging properties that has been linked to oxidative processes 
in cells [2, 12]. 
  Carbamazepine, an anticonvulsant structurally similar to 
tricyclic antidepressants, is used in the management of epi-
lepsy, bipolar disorders and trigeminal neuralgia. Its action is 
related to the stabilization of the inactivated state of the volt-
age-dependent  sodium  channel;  consequently,  carba-
mazepine  reduces  cellular  excitability.  Carbamazepine  has 
been used in the treatment of tinnitus. In studies of tinnitus 
induced by salicylates in rat models, 15 mg/kg i.p. carba-
mazepine  (but  peculiarly,  not  5  mg/kg  or  30  mg/kg)  sup-
pressed the behavioral manifestations of tinnitus [169]. Ver-
tiginous alterations such as vestibular paroxysms have been 
treated with low doses of carbamazepine (200-600 mg per 
day) or oxocarbamazepine; these agents show a rapid benefi-
cial effect. Carbamazepine must be considered a therapeutic 
alternative to the use of gabapentine, valproic acid or pheny-
toin  [145].  Carbamazepine  and  oxocarbazepine  have  also 
been  used  in  the  treatment  of  vertigo  and  particularly  in 
paroxystic  disorders.  In  general,  agents  used  for  the 
treatment  of  epilepsy  seem  promising  in  the  treatment  of 
vertigo of different origins [55, 72, 77]. 
Drugs Acting on Potassium Channels 
  Potassium channels are widely expressed in the nervous 
system. Among ion channels, they exhibit the greatest diver-
sity; at least three major families of potassium channels have 
been defined (2-, 4- and 6-transmembrane segment groups, 
each  with  a  significant  number  of  subfamilies).  Potassium 
channels  play  a  significant  role  in  many  channelopathies,  
and  many  drugs  act  on  these  channels.  However,  in  the  
management  of  vestibular  disorders,  only  one  drug,  3,4-
diaminopyridine, a blocker of voltage-activated K
+ channels 
(Kv1 family with six transmembrane segments in the alpha 
subunit), has been used successfully for the management of 
downbeat  nystagmus  [143].  In  controlled  studies  against 
placebo, it was demonstrated that 3,4-diaminopyridine pro-
duced a significant control of the nystagmus that appears in 
patients with type 2 (EA2) episodic ataxia [144]. The ration-
ale  behind  the  study  was  that  potassium channel blockers 
presumably  increase  the  excitability  of  cerebellar  Purkinje 
cells, thereby augmenting  the inhibitory influence of these 
cells on vestibular and cerebellar nuclei [48, 70]. On the ba-
sis of these results, it has been proposed that aminopyridines 
could have abundant utility in diverse oculomotor disorders 
and in disorders of cerebellar origin [145].  
  Our  research  group  has  generated  evidence  that  low 
threshold voltage-activated potassium current has a signifi-
cant role in the control of the activity of vestibular afferent 
neurons [110, 140]. This current is modulated by the activa-
tion  of  mACh  receptors  (thus,  it  is  called  the  M-current). 
Aside  from  the  fact  that  the  KCNQ  family  of  potassium 
channels are also expressed in transport epithelia involved in 
potassium movement to the endolymph, the functional role 
of the M-current in vestibular afferent neurons allows us to 
suggest the use of retigabine, an activator of the M-current, 
and of linopirdine, a blocker of the M-current, as drugs with 
significant potential for the management of vestibular disor-
ders that may result from an imbalance of the afferent neuron 
activity incoming from each vestibule.  
CONCLUSION 
  Although a large pharmacological arsenal for the treat-
ment of vestibular disorders exists, due to the complexity of 
this organ and to the adaptive processes that compensate for 
vestibular deficits thereby producing a complex evolution of 
vestibular symptomatology, it is extremely difficult to evalu-
ate the effectiveness of commonly used drugs in the treat-
ment of vestibular disorders. Particularly in the case of Mé-
nière's disease, the natural evolution of the disease tends to 
limit the symptoms. In some cases, only the recurrence of 
vertigo episodes, or the evolution of auditory loss, allows the 
clinician to evaluate the real utility of the pharmacological 
treatment. Critical analysis of the existing literature reveals 
that there is a significant lack of information defining  the 
real utility of the diverse drugs used in the clinical treatment 
of  vestibular  disorders  and  that  there  is  a  lack  of  well-
controlled clinical studies utilizing comparative analysis with 
high levels of reliability. However, the development of basic 
studies addressing drug actions at the molecular, cellular and 
systems  level,  combined  with  reliable  and  well  controlled 
clinical trials, will provide  the scientific basis for new ra-
tional strategies for the treatment of vestibular disorders.  
ACKNOWLEDGMENTS 
  This work was partially supported by the National Coun-
cil of Science and Technology of México (CONACyT grant 
46511) to E.S. and by Vicerrectoria de Investigación (VIEP-
BUAP)-CONACyT grants 20/SAL06-G and 20/SAL06-I to 
RV and ES.  
REFERENCES 
[1]  Aantaa,  E.  (1991)  Treatment  of  acute  vestibular  vertigo.  Acta  
Otolaryngol., Suppl. 479, 44-47. 
[2]  Adunka, O., Moustaklis, E., Weber, A., May, A., von Ilberg, C., 
Gstoettner, W., Kierner, A.C. (2003) Labyrinth anesthesia-a forgot-
ten  but  practical  treatment  option  in  Ménière's  disease.  ORL  J. 
Otorhinolaryngol. Relat. Spec., 65, 84-90. 
[3]  Alacio  Casero,  J.,  Ortega  del  Álamo,  P.  (2003)  Efectividad  de 
trimetazidina en pacientes con alteraciones del equilibrio. Estudio 
prospectivo multicéntrico. ORL-DIPS, 30, 184-192. 
[4]  Almanza, A., Vega, R., Soto, E. (2003) Calcium current in type I 
hair cells isolated from the semicircular canal crista ampullaris of 
the rat. Brain Res., 994, 175-180. 
[5]  Anderson, A.D., Troyanovskaya, M., Wackym, P.A. (1997) Differ-
ential  expression  of  alpha2-7,  alpha9  and  beta2-4  nicotinic 
acetylcholine receptor subunit mRNA in the vestibular end-organs 
and Scarpa's ganglia of the rat. Brain Res., 778, 409-413. 
[6]  Andrianov, G.N., Ryzhova, I.V., Tobias, T.V. (2009) Dopaminer-
gic modulation of afferent synaptic transmission in the semicircular 
canals of frogs. Neurosignals, 17, 222-228. 
[7]  Annoni,  J.M.,  Cochran,  S.L.,  Precht,  W.  (1984)  Pharmacology  
of  the  vestibular  hair  cell-afferent  fiber  synapse  in  the  frog.  J. 
Neurosci., 4, 2106-2116. 
[8]  Arab, S.F., Düwel, P., Jüngling, E., Westhofen, M., Lückhoff, A. 
(2004)  Inhibition  of  voltage-gated  calcium  currents  in  type  II  
vestibular hair cells by cinnarizine Naunyn-Schmiedeberg's. Arch. 
Pharmacol., 360, 570-575. Neuropharmacology of Vestibular System Disorders  Current Neuropharmacology, 2010, Vol. 8, No. 1    37 
[9]  Arrang, J.M., Garbarg, M., Quach, T.T., Tuong, D., Yeremian, E., 
Schwartz, J.C. (1985) Actions of betahistine at histamine receptors 
in the brain. Eur. J. Pharmacol., 111, 73-84. 
[10]  Balaban, C.D. (2002) Neural substrates linking balance control and 
anxiety. Physiol Behav., 77, 469-475. 
[11]  Bao, H., Wong, W., Goldberg, J., Eatock, R. (2003) Voltage-gated 
calcium channel currents in type I and type II hair cells isolated 
from the rat crista. J. Neurophysiol., 90, 155-64. 
[12]  Barciszewski,  J.,  Siboska,  G.E.,  Pedersen,  B.O.,  Clark,  B.F.,  
Rattan, S.I. (1997) A mechanism for the in vivo formation of N6-
furfuryladenine, kinetin, as a secondary oxidative damage product 
of DNA. FEBS Lett., 414, 457-460. 
[13]  Barmack, N.H. (2003) Central vestibular system: vestibular nuclei 
and posterior cerebellum. Brain Res. Bull., 60, 511-541. 
[14]  Basile, A.S., Brichta, A.M., Harris, B.D.,  Morse, D., Coling, D., 
Skolnick,  P.  (1999)  Dizocilpine  attenuates  streptomycin-induced 
vestibulotoxicity in rats. Neurosci. Lett., 265, 71-74. 
[15]  Bergquist, F., Dutia, M.B. (2006) Central histaminergic modulation 
of vestibular function -a review. Acta Physiol. Sin., 58, 293-304. 
[16]  Bernard, C., Cochran, S.L., Precht, W. (1985) Presynaptic actions 
of cholinergic agents upon the hair cell-afferent fiber synapse in the 
vestibular labyrinth of the frog. Brain Res., 338, 225-236. 
[17]  Botta, L., Mira, E., Valli, S., Perin, P., Zucca, G., Valli, P. (1998) 
Effects  of  betahistine  on  vestibular  receptors  of  the  frog.  Acta  
Otolaryngol. (Stockh), 118, 519-523. 
[18]  Botta, L., Mira, E., Valli, S., Zucca, G., Perin, P., Benvenuti, C., 
Fossati, A., Valli, P. (2000) Effects of betahistine metabolites on 
frog ampullar receptors. Acta Otolaryngol., 120, 25-27. 
[19]  Botta, L., Tritto, S., Perin, P., Laforenza, U., Gastaldi, G., Zampini, 
V., Zucca, G., Valli, S., Masetto, S., Valli, P. (2008) Histamine H1 
receptors  are  expressed  in  mouse  and  frog  semicircular  canal  
sensory epithelia. Neuroreport, 19, 425-429. 
[20]  Bridgeman,  D.,  Hoffman,  L.,  Wackym,  P.A.,  Micevych,  P.E.,  
Popper, P. (1996) Distribution of choline acetyltransferase mRNA 
in the efferent vestibular neurons of the chinchilla. J. Vestib. Res., 
6, 203-212. 
[21]  Brown, R.E., Stevens, D.R., Haas, H.L. (2001) The physiology of 
brain histamine. Prog. Neurobiol., 63, 637-672. 
[22]  Cameron,  S.A.,  Dutia,  M.B.  (1999)  Lesion-induced  plasticity  
in  rat  vestibular  nucleus  neurones  dependent  on  glucocorticoid 
receptor activation. J. Physiol., 518, 151-158. 
[23]  Carrillo,  E.  (2005)  Efecto  de  cannabinoides  sobre  la  actividad 
eléctrica de las neuronas aferentes de los canales semicirculares. 
Tesis  para  obtener  el  grado  de  Licenciatura  en  Biomedicina,  
facultad  de  Medicina  de  la  Universidad  Autónoma  de  Puebla.  
Mexico. 
[24]  Chambard,  J.M.,  Chabbert,  C.,  Sans,  A.,  Desmadryl,  G.  (1999) 
Developmental changes in low and high voltage-activated calcium 
currents in acutely isolated mouse vestibular neurons. J. Physiol., 
518, 141-149. 
[25]  Chávez, O., Vega, R.,  Soto,  E. (2005) Histamine (H3) receptors 
modulate  the  excitatory  amino  acid  receptor  response  of  the  
vestibular afferent. Brain Res., 1064, 1-9. 
[26]  Darlington, C.L., Dutia, M.B., Smith, P.F. (2002) The contribution 
of  the  intrinsic  excitability  of  vestibular  nucleus  neurons  to  
recovery  from  vestibular  damage.  Eur.  J.  Neurosci.,  15,  1719- 
1727. 
[27]  Darlington,  C.L.,  Smith,  P.F.  (2000)  Molecular  mechanisms  of 
recovery  from  vestibular  damage  in  mammals:  recent  advances. 
Prog. Neurobiol., 62, 313-325. 
[28]  Dayanithi, G., Desmadryl,  G., Travo, C.,  Chabbert, C., Sans,  A. 
(2007)  Trimetazidine  modulates  AMPA/kainate  receptors  in  rat 
vestibular ganglion neurons. Eur J Pharmacol., 574, 8-14. 
[29]  Dhote,  V.,  Balaraman,  R.  (2008)  Anti-oxidant  activity  mediated 
neuroprotective potential of trimetazidine on focal cerebral ischae-
mia-reperfusion injury in rats. Clin. Exp. Pharmacol. Physiol., 35, 
630-637. 
[30]  Dirnagl, U., Iadecola, C.,  Moskowitz, M.A. (1999) Pathobiology  
of ischaemic stroke: an integrated view. Trends Neurosci., 22, 391-
397. 
[31]  Doi, K., Tsumoto, T., Matsunaga, T. (1990) Actions of excitatory 
amino acid antagonists on synaptic inputs to the rat medial vestibu-
lar nucleus: an electrophysiological study in vitro. Exp Brain Res., 
82, 254-262. 
[32]  Dowdy,  E.G.,  Goksen,  N.,  Arnold,  G.E.,  Moore,  W.T.,  Fabian, 
L.W.  (1965)  A  new  treatment  of  Meniere's  disease.  Arch.  
Otolaryngol., 82, 494-497.  
[33]  Drescher, M.J., Drescher, D.G. (1991) N-acetylhistidine, glutamate 
and  beta-alanine  are  concentrated  in  a  receptor  cell  layer  of  the 
trout inner ear. J. Neurochem., 56, 658-664. 
[34]  Düwel, P., Haasler T., Jungling, E., Duong, T.A., Westhofen, M., 
Luckhoff, A. (2005) Effects of cinnarizine on calcium and pres-
sure-dependent  potassium  currents  in  guinea  pig  vestibular  hair 
cells. Naunyn Schmiedebergs Arch. Pharmacol., 371, 441-448. 
[35]  Düwel, P., Jüngling, E., Westhofen, M., Lückhoff, A. (2003) Potas-
sium currents in vestibular type II hair cells activated by hydro-
static pressure. Neuroscience, 116, 963-972. 
[36]  Elgoyhen,  B.,  Vetter,  D.E.,  Katz,  E.,  Rothlin,  C.V.,  Heinemann, 
S.F., Boulter J. (2001) α10: A determinant of nicotinic cholinergic 
receptor  function  in  mammalian  vestibular  and  cochlear  mecha-
nosensory hair cells. Proc. Natl. Acad. Sci., 98, 3501-3506. 
[37]  Estivill,  X.,  Govea,  N.,  Barcelo,  E.,  Badenas,  C.,  Romero,  E., 
Moral,  L.,  Scozzri,  R.,  D´Urbano,  L.,  Zeviani,  M.,  Torroni,  A. 
(1998) Familial progressive sensorineural deafness is mainly due to 
the  mtDNA  A1555G  mutation  and  is  enhanced  by  treatment  of 
aminoglycosides. Am. J. Hum. Genet., 62, 27-35. 
[38]  Eybalin, M. (1993) Neurotransmitters and neuromodulators of the 
mammalian cochlea. Physiol. Rev., 13, 309-373. 
[39]  Flores, A., Soto, E., Vega, R. (2001) Nitric oxide in the afferent 
synaptic  transmission  of  vestibular  system.  Neuroscience,  103, 
459-466. 
[40]  Furman,  J.M.,  Balaban,  C.D.,  Jacob,  R.G.,  Marcus,  D.A.  (2005) 
Migraine-anxiety  related  dizziness  (MARD):  a  new  disorder?  J. 
Neurol. Neurosurg. Psychiatry, 76, 1-8. 
[41]  Furuya,  N.,  Koizumi,  T.  (1998)  Neurotransmitters  of  vestibular 
commissural  inhibition  in  the  cat.  Acta  Otolaryngol.,  118,  64- 
69. 
[42]  Futaki, T., Kitahara, M., Morimoto, M. (1975) Menière's disease 
and diphenidol. A critical analysis of symptoms and equilibrium 
function tests. Acta Otolaryngol., Suppl. 330, 120-128. 
[43]  Ganança, M.M., Caovilla, H.H., Munhoz, M.S., Ganança, C.F., da 
Silva,  M.L.,  Serafini,  F.,  Ganança,  F.F.  (2007)  Optimizing  the 
pharmacological  component  of  integrated  balance  therapy.  Rev. 
Bras. Otorrinolaringol., 73, 12-18. 
[44]  Gates, P. (2005) Hypothesis: could Meniere's disease be a chan-
nelopathy? Intern Med. J., 35, 488-489. 
[45]  Gilling, K., Jatzke, C., Wollenburg, C., Vanejevs, M., Kauss, V., 
Jirgensons,  A.,  Parsons,  C.G.  (2007)  A  novel  class  of  amino-
alkylcyclohexanes  as  uncompetitive,  fast,  voltage-dependent,  N-
methyl-D-aspartate (NMDA) receptor antagonists-in vitro charac-
terization. J. Neural Transm., 114, 1529-1537.  
[46]  Gil-Loyzaga, P., Hernández, E., Carricondo, F., Simón, F., Poch-
Broto, J. (1999) Trimetazidine prevents cochlear lesions induced by 
intraperitoneal  and  perilymphatic  administration  o  kainic  acid. 
Brain Res., 826, 93-103. 
[47]  Gil-Loyzaga,  P.,  Vicente-Torres,  M.A.,  García-Bonacho,  M.,  
Esquifino, A. (1997) Presence of catecholamines and serotonin in 
the rat vestibule. Brain Res., 746, 265-268. 
[48]  Gittis,  A.H.,  du  Lac  S.  (2007)  Firing  properties  of  GABAergic 
versus non-GABAergic vestibular nucleus neurons conferred by a 
differential  balance  of  potassium  currents.  J.  Neurophysiol,,  97, 
3986 -3996. 
[49]  Gliddon, C.M., Sansom, A.J., Smith, P.F., Darlington, C.L. (2000) 
Effects  of  intra-vestibular  nucleus  injection  of  the  group  I  me-
tabotropic glutamate receptor antagonist AIDA on vestibular com-
pensation in guinea pigs. Exp. Brain Res., 134, 74-80. 
[50]  Goldberg, J., Fernández, C. (1980) Efferent vestibular system in the 
squirrel monkey: anatomical localization and influence on afferent 
activity. J. Neurophysiol., 43, 986-1025. 
[51]  Gordon,  C.R.,  Shupak,  A.  (1999)  Prevention  and  treatment  of  
motion sickness in children. CNS Drugs, 12, 369-381. 
[52]  Guth, P., Perin, P., Norris, C.H., Valli,  P. (1998) The vestibular 
hair cells: post-transductional signal processing. Prog. Neurobiol., 
54, 193-247. 
[53]  Guth, P.S., Shipon, S., Valli, P., Mira, E., Benvenuti, C. (2000) A 
pharmacological analysis of the effects of histamine and betahistine 
on the semicircular canal. In: Vertigine e betaistine Benvenuti, C. 
Ed. Formenti, Milan, Italy. pp. 43-60. 38    Current Neuropharmacology, 2010, Vol. 8, No. 1  Soto and Vega 
[54]  Hahn,  A.,  Sejna,  I.,  Stefflova,  B.,  Schwarz,  M.,  Baumann,  W. 
(2008)  A  fixed  combination  of  Cinnarizine  /Dimenhydrinate  for  
the  Treatment  of  Patients  with  Acute  Vertigo  Due  to  Vestibular 
disorders: A Randomized, reference-controlled clinical study. Clin. 
Drug Investig., 28, 89-99. 
[55]  Hain, T.C., Uddin, M. (2003) Pharmacological treatment of ver-
tigo. CNS Drugs, 17, 85-100. 
[56]  Halberstadt,  A.L.,  Balaban,  C.D.  (2007)  Selective  anterograde 
tracing of the individual serotonergic and nonserotonergic compo-
nents of the dorsal raphe nucleus projection to the vestibular nuclei. 
Neuroscience, 147, 207-223. 
[57]  Hamzavi,  J.,  Schmetterer,  L.,  Formanek,  M.  (2002)  Vestibular 
symptoms  as  a complication of  sildenafil:  a  case  report.  Wiener 
Klin. Wochensch. 114, 54-55. 
[58]  Harvey, S.C., Li, X., Skolnick, P., Kirst, H.A. (2000) The antibac-
terial and NMDA receptor activating properties of aminoglycosides 
are dissociable. Eur. J. Pharmacol., 387, 1-7. 
[59]  Highstein, S.M., Baker, R. (1985) Action of the efferent vestibular 
system on primary afferents in the toadfish, Opsanus tau. J. Neuro-
physiol., 54, 370-384. 
[60]  Highstein, S.M., Holstein, G.R. (2006) The Anatomy of the vesti-
bular nuclei. Prog. Brain Res., 151, 157-203. 
[61]  Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shank-
ley, N.P., Young, J.M., Schunack, W., Levi, R., Haas, H.L. (1997) 
International Union of Pharmacology. XIII. Classification of his-
tamine receptors. Pharmacol. Rev., 49, 253-278. 
[62]  Holstein,  G.R.,  Martinelli,  G.P.,  Boyle,  R.,  Rabbitt,  R.D.,  High-
stein, S.M. (2004) Ultrastructural observations of efferent terminals 
in the crista Ampullaris of the toadfish. opsanus tau. Exp. Brain 
Res., 155, 265-273. 
[63]  Holstein, G.R., Martinelli, G.P., Cohen, B. (1999) The ultrastruc-
ture  of  GABA-immunoreactive  vestibular  commissural  neurons  
related to velocity storage in the monkey. Neuroscience, 93, 171-
181. 
[64]  Horii, A., Takeda, N., Matsunaga, A., Yamatodani, T., Mochizuki, 
K., Okakura-Mochizuki, K., Wada, H. (1993) Effect of unilateral 
vestibular stimulation on histamine release from hypothalamus of 
rats in vivo. J. Neurophysiol., 70, 1822-1826. 
[65]  Housley,  G.D.,  Norris,  C.H.,  Guth,  P.S.  (1988)  Histamine  and 
related substances influence neurotransmission in the semicircular 
canal. Hear Res., 35, 87-98. 
[66]  Irving, C., Richman, P., Kaiafas, C., Eskin, B., Allegra, J. (2002) 
Intramuscular  droperidol  versus  intramuscular  dimenhydrinate  
for  the  treatment  of  acute  peripheral  vertigo  in  the  emergency  
department: a randomized clinical trial. Acad. Emerg. Med., 9, 650-
653. 
[67]  Ishiyama,  A.,  López,  I.,  Wackym,  P.A.  (1997)  Molecular  
characterization  of  muscarinic  receptors  in  the  human  vestibular 
periphery. Implications for pharmacotherapy. Am. J. Otol., 18, 648-
654. 
[68]  Jackson, R.T., Turner, J.S. (1987) Astemizole: its use in the treat-
ment of patients with cronic vertigo. Arch. Otolaryngol. Head Neck 
Surgery, 113, 536-542. 
[69]  Janowsky, D.S., Risch, S.C., Ziegler, M., Kennedy, B., Huey, L. 
(1984)  A  cholinomimetic  model  of  motion  sickness  and  space  
adaptation syndrome. Aviat. Space Environ. Med., 55, 692-696. 
[70]  Jen,  J.C.,  Graves,  T.D.,  Hess,  E.J.,  Hanna,  M.G.,  Griggs,  R.C., 
Baloh,  R.W.  (2007)  Primary  episodic  ataxias:  diagnosis,  patho-
genesis and treatment. Brain, 130, 2484-2493. 
[71]  Johnson, W.H., Fenton, R.S., Evans, A. (1976) Effects of droperi-
dol in management of vestibular disorders. Laryngoscope, 86, 946-
954.  
[72]  Kanashiro, A.M., Alexandre, P.L., Pereira, C.B., Melo, A.C., Scaff, 
M. (2005) Vestibular paroxysmia: clinical study and treatment of 
eight patients. Arq. Neuropsiquiatr., 63, 643-647. 
[73]  Kataoka, Y., Ohmori, H. (1996) Of known neurotransmitters, glu-
tamate is the most likely to be released from chick cochlear hair 
cells. J. Neurophysiol., 76, 1870-1879. 
[74]  Kawabata, A., Sasa, M., Ujihara, H., Takaori, S. (1990) Inhibition 
by enkephalin of medial vestibular nucleus neurons responding to 
horizontal pendular rotation. Life Sci., 47, 1355-1363. 
[75]  Kingma,  H.,  Bonink,  M.,  Meulenbroeks,  A.,  Konjinenberg,  H. 
(1997) Dose-dependent effect of betahistine on the vestibulo-ocular 
reflex:  a  double  blind,  placebo  controlled  study  in  patients  with 
paroxysmal vertigo. Acta Otolaryngol., 117, 641-646. 
[76]  Kirsten, E.B., Sharma, J.N. (1976) Microiontophoresis of acetyl-
choline, histamine and their antagonist on neuron on the medial and 
lateral vestibular nuclei of the cat. Neuropharmacology, 15, 743-
753. 
[77]  Knox, G.W., Woodard, D., Chelen, W., Ferguson, R., Johnson, L. 
(1994) Phenytoin for motion sickness: clinical evaluation. Laryn-
goscope, 104, 935-939. 
[78]  Kroese, A.B.A., Das,  A., Hudspeth, A.J. (1989) Blockage of the 
transduction  channels  of  hair  cells  in  the  bullfrog's  sacculus  by 
aminoglycoside antibiotics. Hear Res., 37, 203-218. 
[79]  Lacour, M. (2006) Restoration of vestibular function: basic aspects 
and practical advances for rehabilitation. Curr. Med. Res. Opin., 
22, 1651-1659. 
[80]  Lacour, M., Sterkers, O. (2001) Histamine and betahistine in the 
treatment of vertigo. CNS Drugs, 15, 853-870. 
[81]  Lamm, K., Arnold, W. (2000) The effect of blood flow promoting 
drugs  on  cochlear  blood  flow,  perilymphatic  pO2  and  auditory 
function in the normal and noise-damaged hypoxic and ischemic 
guinea pig inner ear. Hearing Res., 141, 199-219. 
[82]  Landmark,  C.J.  (2007)  Targets  for  antiepileptic  drugs  in  the  
synapse. Med. Sci. Monit., 13, RA1-7. 
[83]  Lassen, L.F., Hirsch, B.F., Kamerer, D.B. (1996) Use of nimodip-
ine in the medical treatment of Meniere’s disease: clinical experi-
ence. Am J Otol., 17, 577-580. 
[84]  Leurs, R., Bakker, R.A., Timmerman, H., de Esch I.J. (2005) The 
histamine  H3  receptor:  from  gene  cloning  to  H3  receptor drugs. 
Nat. Rev. Drug Discov., 4, 107-120. 
[85]  Limón,  A.,  Pérez,  C.,  Vega,  R.,  Soto,  E.  (2005)  IK,Ca  current  
density is correlated with soma size in vestibular primary afferent 
neurons. J. Neurophysiol., 94, 3751-3761. 
[86]  Linder, S., Borgeat, A., Biollaz, J. (1989) Meniere-like syndrome 
following  epidural  morphine  analgesia.  Anesthesiology,  71,  782-
783. 
[87]  Lioudyno, M.I., Verbitsky, M., Glowatzki, E., Holt, J.C., Boulter, 
J.,  Zadina,  J.E.,  Elgoyhen,  A.B.,  Guth,  P.S.  (2002)  The  
alpha9/alpha10-containing  nicotinic  ACh  receptor  is  directly  
modulated  by  opioid  peptides,  endomorphin-1,  and  dynorphin  
B,  proposed  efferent  cotransmitters  in  the  inner  ear.  Mol.  Cell  
Neurosci., 20, 695-711. 
[88]  Magnusson, A.K., Tham, R. (2003) Vestibulo-oculomotor behav-
iour in rats following a transient unilateral vestibular loss induced 
by lidocaine. Neuroscience, 120, 1105-1114. 
[89]  Martí  Massó,  J.F.,  Martí,  I.,  Carrera,  N.,  Poza,  J.J.,  López  de 
Munain, A. (2005) Trimetazidine induces parkinsonism, gait disor-
ders and tremor. Therapie, 60, 419-422. 
[90]  Martínez, D.M. (1972) The effect of Serc (betahistine hydrochlo-
ride) on the circulation of the inner ear in experimental animals. 
Acta Otolaryngol., Suppl. 305, 29-47. 
[91]  Martini, A., de Domenico F. (1990) Trimetazidine versus betahis-
tine in Meniere's disease. A double blind study. Ann. Otolaryngol. 
Chir. Cervicofac., 107(Suppl 1), 20-27. 
[92]  Matsuoka, I., Domino, E.F. (1975) Cholinergic mechanisms in the 
cat vestibular system. Neuropharmacology, 14, 201-210. 
[93]  Matsuoka, I., Ito, J., Takahashi, H., Sasa, M., Takaori, S. (1984) 
Experimental vestibular pharmacology: a minireview with special 
reference  to  neuroactive  substances  and  antivertigo  drugs.  Acta 
Otolaryngol., Suppl. 419, 62-70. 
[94]  Meza, G. (2008) Modalities of GABA and glutamate neurotrans-
mission in the vertebrate inner ear vestibule. Neurochem. Res., 33, 
1634-1642. 
[95]  Michna, M., Knirsch, M.,  Hoda, J.C.,  Muenkner, S., Langer, P., 
Platzer,  J.,  Striessnig,  J.,  Engel,  J.  (2003)  Cav1.3  (α1D)  Ca
2+  
currents in neonatal outer hair cells of mice. J. Physiol., 553, 747-
758. 
[96]  Minor, L.B., Schessel, D.A., Carey, J.P. (2004) Meniere’s disease 
[review]. Curr. Opin. Neurol., 17, 9-16. 
[97]  Mira,  E.,  Guidetti,  G.,  Ghilardi,  L.,  Fattori,  B.,  Malannino,  
N., Maiolino, L., Mora, R., Ottoboni, S., Pagnini, P., Leprini, M., 
Pallestrini,  E.,  Passali,  D.,  Nuti,  D.,  Russolo,  M.,  Tirelli,  G.,  
Simoncelli, C., Brizi, S., Vicini, C., Frasconi, P. (2003) Betahistine 
dihydrochloride  in  the  treatment  of  peripheral  vestibular  vertigo. 
Eur. Arch. Otorhinolaryngol., 260, 73-77. 
[98]  Mira,  E.  (2008)  Improving  the  quality  of  life  in  patients  with  
vestibular  disorders:  the  role  of  medical  treatments  and physical  
rehabilitation. Int. J. Clin. Pract., 62, 109-114.  Neuropharmacology of Vestibular System Disorders  Current Neuropharmacology, 2010, Vol. 8, No. 1    39 
[99]  Morita, M., Takeda, N., Hasegawa, S., Yamatodani, A., Wada, H., 
Sakai,  S.,  Kubo,  T.,  Matsunaga,  T.  (1990)  Effects  of  anti-
cholinergic and cholinergic drugs on habituation to motion in rats. 
Acta Otolaryngol., 110, 196-202. 
[100]  Nabatame,  H.,  Sasa,  M.,  Ohno,  Y.,  Takaori,  S.,  Kameyama,  
M.  (1986)  Activation  of  Lateral  Vestibular  Nucleus  Neurons  by 
lontophoretically  Applied  Phencyclidine. Jpn.  J.  Pharmacol.,  42, 
117-122. 
[101]  Nachum, Z., Shupak, A., Gordon, C.R.  (2006) Transdermal sco-
polamine for prevention of motion sickness: clinical pharmacoki-
netics and therapeutic applications. Clin. Pharmacokinet., 45, 543-
66. 
[102]  Novotný, M., Kostrica, R. (2002) Fixed combination of cinnarizine 
and dimenhydrinate versus betahistine dimesylate in the treatment 
of  Ménière's  disease:  a  randomized,  double-blind,  parallel  group 
clinical study. Int. Tinnitus J., 8, 115-123. 
[103]  Oestreicher,  E.,  Arnold,  W.,  Ehrenberger,  K.,  Felix,  D.  (1998) 
Memantine  suppresses  the  glutamatergic  neurotransmission  of 
mammalian inner hair cells. J. Otorhinolaryngol. Relat. Spec., 60, 
18-21. 
[104]  Oliver, D., Ludwig, J., Reisinger, E., Zoellner, W., Ruppersberg, 
J.P.,  Fakler,  B.  (2001)  Memantine  inhibits  efferent  cholinergic 
transmission  in  the  cochlea  by  blocking  nicotinic  acetylcholine  
receptors of outer hair cells. Mol. Pharmacol., 60, 183-189. 
[105]  Pane-Pianese,  C.P.,  Hidalgo,  L.O.V.,  González,  R.H.,  Madrid, 
C.E., Ponce, J.E.C., Ramírez, A.M., Moran, L.M., Arenas, J.E.P., 
Rubio,  A.T.Y.G.,  Uribe,  J.O.,  Abiuso,  J.,  Hanuch,  J., Alegria  J, 
Volpi, J., Flaskamp, R., Sanjuan, A.P., Gómez, J.M.G., Hernández, 
J., Pedraza, A., Quijano, D., Martínez, C., Castañeda, J.R., Guerra, 
S.J.C., Valencia, G.F. (2002) New approaches to the management 
of peripheral vertigo: Efficacy and safety of two calcium antago-
nists  in  a  12-week,  multinational,  double-blind  study.  Otol.  
Neurotol., 23, 357-363. 
[106]  Panula, P., Flugge, G., Fuchs, E., Pirvola, U., Auvinen, S., Airaksi-
nen,  M.S.  (1989)  Histamine-immunoreactive  nerve  fibers  in  the 
mammalian spinal cord. Brain Res., 484, 234-239. 
[107]  Paul,  M.A.,  MacLellan,  M.,  Gray,  G.  (2005)  Motion-sickness 
medications  for  aircrew:  impact  on  psychomotor  performance. 
Aviat. Space Environ. Med., 76, 560-565. 
[108]  Perachio, A.A., Kevetter, G.A. (1989) Identification of vestibular 
efferent neurons in the gerbil: histochemical and retrograde label-
ling. Exp. Brain Res., 78, 315-326. 
[109]  Pérez,  M.E.,  Soto,  E.,  Vega,  R.  (1991)  Streptomycin  blocks  the 
postsynaptic effects of excitatory amino acids on the vestibular sys-
tem primary afferents. Brain Res., 563, 221-226. 
[110]  Pérez, C., Limón, A., Vega, R.,  Soto, E. (2009) The muscarinic 
inhibition  of  the  potassium  M-current  modulates  the  action-
potential discharge in the vestibular primary-afferent neurons of the 
rat. Neuroscience, 158, 1662-1674. 
[111]  Pérez-Fernández, N., Vázques de la Iglesia F. (2003) Tratamiento 
médico del vértigo. Rev. Med. Univ. Navarra, 47, 60-63. 
[112]  Perin,  P.,  Soto,  E.,  Vega,  R.,  Botta,  L.,  Masetto,  S.,  Zucca,  G., 
Valli, P. (2000) Calcium channels functional roles in the frog semi-
circular canal. NeuroReport., 11, 417-420. 
[113]  Plazas, P.V., Savino J, Kracun S, Gómez-Casati, M.E., Katz, E., 
Parsons, C.G., Millar, N.S., Elgoyhen, A.B. (2007) Inhibition of the 
alpha9-alpha10  nicotinic  cholinergic  receptor  by  neramexane,  an 
open  channel  blocker  of N-methyl-D-aspartate  receptors. Eur.  J. 
Pharmacol., 566, 11-19. 
[114]  Popper,  P.,  Cristobal,  R.,  Wackym,  P.A.  (2004)  Expression  and 
distribution  of  mu  opioid  receptors  in  the  inner  ear  of  the  rat.  
Neuroscience, 129, 225-233. 
[115]  Popper,  P.,  Rodrigo,  J.P.,  Álvarez,  J.C.,  López,  I.,  Honrubia,  
V.  (1997)  Expression  of  the  AMPA-selective  receptor  subunits  
in the vestibular nuclei of the chinchilla. Mol. Brain Res., 44, 21-
30. 
[116]  Prigioni, I., Russo, G., Valli, P., Masetto, S. (1990) Pre-and post-
synaptic excitatory action of glutamate agonist on frog vestibular 
receptors. Hear Res., 46, 253-260. 
[117]  Rascol,  O.,  Hain,  T.C.,  Brefel,  C.,  Benazet,  M.,  Clanet,  M.,  
Montastruc, J.L. (1995) Antivertigo medications and drug-induced 
vertigo: A pharmacological review. Drugs, 50, 777-791. 
[118]  Rassekh, C.H., Harker, L.A. (1992) The prevalence of migraine in 
Ménière's disease. Laryngoscope, 102, 135-138. 
[119]  Renner,  U.,  Oertel,  R.,  Kirch,  W.  (2005)  Pharmacokinetics  and 
pharmacodynamics  in  clinical  use  of  scopolamine.  Ther.  Drug 
Monit., 27, 655-665. 
[120]  Rodríguez, U., Carrillo, E., Soto, E. (2005) Cannabinoides: neuro-
biología y usos médicos. Elementos, 60, 3-9. 
[121]  Ryan, A.F., Simmons, D.M., Watts, A.G., Swanson, L.W. (1991) 
Enkephalin mRNA production by cochlear and vestibular efferent 
neurons in the gerbil brainstem. Exp. Brain Res., 87, 259-267. 
[122]  Sakata, E., Nakazawa, H., Iwashita, N. (1984) Therapy of tinnitus. 
Tympanic cavity infusion of lidocaine and steroid solution. Auris 
Nasus Larynx., 11, 11-18. 
[123]  Scholtz, A.W., Schwarz, M., Baumann, W., Kleinfeldt, D., Scholtz, 
H.J. (2004) Treatment of vertigo due to acute unilateral vestibular 
loss with a fixed combination of cinnarizine and dimenhydrinate: a 
double-blind, randomized, parallel-group clinical study. Clin Ther., 
26, 866-877. 
[124]  Schuerger,  R.J.,  Balaban,  C.D.  (1999)  Organization  of  the  
coeruleo-vestibular pathway  in  rats,  rabbits,  and  monkeys. Brain 
Res. Rev., 30, 189-217. 
[125]  Sekitani, T., McCabe, B.F., Ryu, J.H. (1971) Drug effects on the 
medial vestibular nucleus. Arch. Otolaryngol., 93, 581-589. 
[126]  Serafin, M., Khateb, A., de Waele, C., Vidal, P.P., Mühlethaler, M. 
(1990) Low threshold calcium spikes in medial vestibular nuclei 
neurones in vitro: a role in the generation of the vestibular nystag-
mus quick phase in vivo? Exp. Brain Res., 82, 187-190. 
[127]  Serafin, M., de Waele, C., Khateb, A., Vidal, P.P., Mühlethaler, M. 
(1991) Medial vestibular nucleus in the guinea-pig: II. Ionic basis 
of the intrinsic membrane properties in brainstem slices. Exp. Brain 
Res., 84, 426-433. 
[128]  Seidman,  M.D.,  Van  de  Water,  T.R.  (2003)  Pharmacologic  
manipulation of the labyrinth with novel and traditional agents de-
livered to the inner ear. Ear, Nose Throat J., 82, 276-288. 
[129]  Sivet,  J.,  de  la  Gastine,  B.,  Mosquet,  B.,  Lescure,  P.,  Boutemy,  
J.,  Le  Boisselier,  R.,  Coquerel,  A.  (2008)  Trimetazidine-induced 
encephalopathy  with  choreiform  disorders:  A  case  report.  Rev. 
Med. Intern., 29, 512-515.  
[130]  Smith, P.F., Darlington, C.L. (1997) The contribution of N-methyl-
daspartate  receptors  to  lesion-induced  plasticity  in  the  vestibular 
nucleus. Prog. Neurobiol., 53, 517-531. 
[131]  Smith,  P.F,  Darlington,  C.L.  (1996)  Recent  advances  in  the  
pharmacology  of  the  vestibulo-ocular  reflex  system.  Trends  
Pharmacol. Sci., 17, 421-427. 
[132]  Smith,  P.F.,  Ashton,  J.C.,  Darlington,  C.L.  (2006)  The  endocan-
nabinoid system: A new player in the neurochemical control of ves-
tibular function? Audiol. Neurootol., 11, 207-212. 
[133]  Smith, P.F., Zheng, Y., Paterson, S., Darlington, C.L. (2001) The 
contribution of nitric oxide to vestibular compensation: are there 
species differences? Acta Otolaryngol., Suppl. 545, 57-60. 
[134]  Smith, W.K., Sankar, V., Pfleiderer, A.G. (2005) A national survey 
amongst UK otolaryngologists regarding the treatment of Meniere's 
disease. J. Laryngol. Otol., 119, 102-105. 
[135]  Smith, M.R., Nelson, A.B., Du Lac, S. (2002) Regulation of firing 
response  gain  by  calcium-dependent  mechanisms  in  vestibular  
nucleus neurons. J. Neurophysiol., 87, 2031-2042. 
[136]  Soto, E., Limón, A., Ortega, A., Vega, R. (2002) Características 
morfológicas  y  electrofisiológicas  de  las  neuronas  del  ganglio  
vestibular en cultivo. Gaceta Méd. México., 138, 1-14. 
[137]  Soto, E., Vega, R. (1988) Actions of excitatory aminoacid agonists 
and antagonists on the primary afferents of the vestibular system  
of  the  axolotl  (Ambystoma  mexicanum).  Brain  Res.,  462,  104- 
111. 
[138]  Soto,  E.,  Chávez,  H.,  Valli,  P.,  Benvenuti,  C.,  Vega,  R.  (2001) 
Betahistine produces a postsynaptic inhibition on the excitability  
of the primary afferent neurons in the vestibular endorgans. Acta 
Otolaryngol., Suppl. 121, 19-24. 
[139]  Soto, E., Flores, A., Erostegui, C., Vega, R. (1994) Evidence for 
NMDA receptor in the afferent synaptic transmission of the vesti-
bular system. Brain Res., 633, 289-296. 
[140]  Soto,  E.,  Pérez,  C.,  Limón,  A.,  Chávez,  H.,  Vega,  R.  (2004)  M 
Current in Vestibular Afferent Neurons from the Rat. J. Vest. Res., 
14, 190. 
[141]  Spinks,  A.B.,  Wasiak,  J.,  Villanueva,  E.V.,  Bernath,  V.  (2007) 
Scopolamine (hyoscine) for preventing and treating motion sick-
ness. Cochrane Database Syst. Rev., 18, CD002851. 40    Current Neuropharmacology, 2010, Vol. 8, No. 1  Soto and Vega 
[142]  Stahl,  J.S.,  Rottach,  K.G.,  Averbuch-Heller,  L.,  Maydell,  R.D., 
Collins,  S.D.,  Leigh,  R.J.  (1996)  A  pilot  study of  gabapentin  as 
treatment for acquired nystagmus. Neuro-ophthalmology, 16, 107-
113. 
[143]  Straube, A. (2005) Pharmacology of vertigo/nystagmus/oscillopsia. 
Curr. Opin. Neurol., 18, 11-14. 
[144]  Strupp,  M.,  Schüler,  O.,  Krafczyk,  S.,  Jahn,  K.,  Schautzer,  F., 
Büttner, U., Brandt, T. (2003) Treatment of downbeat nystagmus 
with 3,4-diaminopyridine: a placebo-controlled study. Neurology, 
61, 165-170. 
[145]  Strupp,  M.,  Brandt,  T.  (2006)  Pharmacological  advances  in  the 
treatment of neuro-otological and eye movement disorders. Curr. 
Opin. Neurol., 19, 33-40. 
[146]  Sulaiman, M.R., Dutia, M.B. (1998) Opioid inhibition of rat medial 
vestibular  nucleus  neurones in  vitro  and  its  dependence  on  age. 
Exp. Brain Res., 122, 196-202. 
[147]  Sulaiman,  M.R.,  Niklasson,  M.,  Tham,  R.,  Dutia,  M.B.  (1999) 
Modulation of vestibular function by nociceptin/orphanin FQ: an in 
vivo and in vitro study. Brain Res., 828, 74-82. 
[148]  Takahashi, Y., Tsumoto, T., Kubo, T. (1994) N-Methyl-d-aspartate 
receptors contribute to afferent synaptic transmission in the medial 
vestibular nucleus of young rats. Brain Res., 659, 287-291. 
[149]  Tighilet, B., Lacour, M. (1998) Distribution of choline acetyltrans-
ferase  immunoreactivity  in  the  vestibular  nuclei  of  normal  and  
unilateral  vestibular  neurectomized  cats.  Eur.  J.  Neurosci.,  10, 
3115-3126. 
[150]  Tighilet, B.,  Trottier, S.,  Lacour, M. (2005) Dose- and duration-
dependent  effects  of  betahistine  dihydrochloride  treatment  on  
histamine turnover in the cat. Eur. J. Pharmacol., 523, 54-63. 
[151]  Tighilet,  B.,  Lacour,  M.  (1996)  Distribution  of  histamine  
axonal  fibres  in  the vestibular nuclei  in  the  cat. Neuroreport,  7, 
873-878. 
[152]  Tomoda,  K.,  Nagata,  M.,  Harada,  N.,  Iwai,  H.,  Yamashita,  T. 
(1997)  Effect of  histamine  on  intracellular  Ca
2+  concentration  in 
guinea pig isolated vestibular hair cells. Acta Otolaryngol., Suppl. 
528, 37-40. 
[153]  Tritto, S., Botta, L., Zampini, V., Zucca, G., Valli, P., Masetto, S. 
(2009) Calyx and dimorphic neurons of mouse Scarpa's ganglion 
express histamine H3 receptors. BMC Neurosci., 10, 70.  
[154]  Valli,  P.,  Caston,  J.,  Zucca,  G.  (1984)  Local  mechanisms  in  
vestibular  receptor  control.  Effects  of  curare  on  the  EPSPs  and 
spike discharge recorded from single afferent fibres of the posterior 
canal nerve of the frog. Acta Otolaryngol., 97, 611-618. 
[155]  Varoli,  L.,  Andreani,  A.,  Burnelli,  S.,  Granaiola,  M.,  Leoni,  A., 
Locatelli,  A.,  Morigi,  R.,  Rambaldi,  M.,  Bedini,  A.,  Fazio,  N., 
Spampinato,  S.  (2008)  Diphenidol-related  diamines  as  novel  
muscarinic M4 receptor antagonists. Bioorg. Med. Chem. Lett., 18, 
2972-2976. 
[156]  Vega,  R.,  Soto,  E.  (2003)  Opioid  peptide  receptors  mediates  an 
inhibitory presynaptic and excitatory postsynaptic input to the ves-
tibulat afferent neurons. Neuroscience, 118, 75-85. 
[157]  Vega, R., Soto, E., Budelli R., González Estrada, M.T. (1987) Is 
GABA an afferent transmitter in the vestibular system ? Hear Res., 
29, 169-178. 
[158]  Vidal,  P.P.,  Babalian,  A.,  de  Waele,  C.,  Serafin,  M.,  Vibert,  N., 
Mühlethaler, M. (1996) NMDA receptors of the vestibular nuclei 
neurones. Brain Res Bull., 40, 347-352. 
[159]  Wackym, P.A., Popper, P., López, I., Ishiyama, A., Micevych, P.E. 
(1995)  Expression  of  alpha  4  and  beta  2  nicotinic  acetylcholine  
receptor  subunit  mRNA  and  localization  of  alpha-bungarotoxin 
binding proteins in the rat vestibular periphery. Cell Biol. Int., 19, 
291-300.  
[160]  Wackym, P.A., Chen, C.T., Ishiyama, A., Pettis, R.M., López, I.A., 
Hoffman,  L.  (1996)  Muscarinic  acetylcholine  receptor  subtype 
mRNA  in  the  human  and  rat  vestibular  periphery.  Cell  Biol.  
Intern., 20, 187-192. 
[161]  Walberg,  F.,  Ottersen,  O.P.,  Rinvik,  E.  (1990)  GABA,  glycine, 
aspartate, glutamate and taurine in the vestibular nuclei: an immu-
nocytochemical investigation in the cat. Exp. Brain Res., 79, 547-
563. 
[162]  Wang, J.J., Dutia, M.B. (1995) Effects of histamine and betahistine 
on rat medial vestibular nucleus neurones: possible mechanism of 
action of anti-histaminergic drugs in vertigo and motion sickness. 
Exp. Brain Res., 105, 18-24. 
[163]  Wood, C.D., Graybiel, A. (1973) The antimotion sickness drugs. 
Otolaryngol. Clin North Am., 6, 301-313. 
[164]  Yacobino,  D.A.,  Hain,  T.C.  (2004)  Farmacología  de  las  altera-
ciones vestibulares. Rev. Neurol., 39, 381-387. 
[165]  Yamanaka, T., Him, A., Cameron, S.A., Dutia, M.B. (2000) Rapid 
compensatory changes in GABA receptor efficacy in rat vestibular 
neurones  after  unilateral  labyrinthectomy.  J.  Physiol.,  523,  413-
424. 
[166]  Zajonc, T.P., Roland, P.S. (2005) Vertigo and motion sickness. Part 
II: Pharmacologic treatment. Ear Nose Throat J., 85, 25-35. 
[167]  Zee, D.S. (1985) Mechanisms of nystagmus. Am J Otol. Suppl: 30-4. 
[168]  Zhang,  J.,  Han,  X.H.,  Li,  H.Z.,  Zhu,  J.N.,  Wang,  J.J.  (2008)  
Histamine  excites  rat  lateral  vestibular  nuclear  neurons  through  
activation of post-synaptic H2 receptors. Neurosci. Lett., 448, 15-
19.  
[169]  Zheng,  Y.,  Hooton,  K.,  Smith,  P.F.,  Darlington,  C.L.  (2007)  
Carbamazepine reduces the behavioural manifestations of tinnitus 
following salicylate treatment in rats. Acta Otolaryngol., 22, 1-5. 
 
Received: November 19, 2009  Revised: December 17, 2009  Accepted: January 08, 2010 
 
 
 